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1. ABSTRACT: 
Prevalence of Type II diabetes is increasing globally as well as in India day by day. 
Asian Indians have racial predisposition for Diabetes. Urban India is getting 
industrialized rapidly and Diabetes is now one of the most common non-
communicable diseases globally. The country is already being dubbed as the 
“Diabetes Capital of the World” 
 
Governments and medical fraternity across the world have acknowledged that the 
diabetes is increasing at epidemic rates and affecting all countries. For the first time 
non infectious disease has been seen as posing as serious a global health threat as 
infectious epidemics such as HIV/AIDS. Today, diabetes has affected 250 million 
people or around 6 % of the world’s adult population. 
As per Diabetes Atlas, population of diabetes is 194 millions in 2003 and projected to 
333 millions by 2025.(22)The World Health Organization (WHO) has projected that 
the global prevalence of type 2 diabetes mellitus will be more than double from 135 
millions in 1995 to 300 millions by 2025. 
 
Prevalence of Diabetes in the world was 5.1 % in 2003 and by 2025 it will be around 
6.5%. IGT prevalence in the world was 8.2 % in 2003 and projected to be 9.0% in 
2025 (age group 20-79 years). 
 
International Diabetes Federation estimates that the number of diabetic patients in 
India is more than doubled from 19 million in 1995 to 40.9 million in 2007.It is 
projected to increase by 69.9 million by 2025. This means by 2025 there are nearly 
around 7 crores people will have diabetes. 
 
Currently up to 11 % of India’s urban population and 3 % of rural population above 
the age of 15 have diabetes. It has been demonstrated, that industrialization and 
modernization lead to sedentary lifestyle, obesity and higher risk of metabolic 
disorders.  
 
The risk variables associated with diabetes are almost similar in all nations, but its 
expressions and intensities vary widely between different races and countries. 
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The prevalence of diabetes mellitus differs in all the states of India across the rural & 
urban area. This is because of the different dietary pattern, physical activity and 
mental status. 
 
In year 2007 & 2008, a cross sectional survey was conducted via mode of camps at 
various urban and rural part of Gujarat. After obtaining a proper consent form, 
comprehensive questionnaire was used to collect the various anthropological details, 
physical examination and blood collection was performed from around 1700 subjects 
> 20 years of age from the different area of Gujarat. Chi square test was used for all 
categorical comparisons. Also multiple logistic regression was used for detailed 
exploratory analysis. 
 
We have focused mainly on prediabetes covering both Impaired Fasting Glucose 
(IFG) and Impaired Glucose Tolerance (IGT). We also identified the relationship of 
Waist to Hip ratio(WHR),Body Mass Index(BMI),systolic blood pressure, Diastolic 
blood pressure, Serum Triglycerides, Serum Cholesterol, Serum LDL and Serum 
HDL on prediabets.We have also evaluated impact of family history of diabetes on 
the development of prediabetes.  
 
We have also evaluated the correlation of prediabets with the age and found striking 
observation that the prevalence of prediabets is higher after age of 40 years. 
 
The crude prevalence of IFG in Gujarati population is around 4.23 % and IGT is 
around 6.82 %.But the age adjusted prevalence of IFG is around 2.72% and IGT is 
around 4.67%.If we extrapolate these, it indicates that around 1.3 million people are 
having impaired fasting glucose and around 2.3 million people have impaired glucose 
tolerance. The prevalence of IGT found more after age of 40 years.  
 
For IFG, there is increase after age of 40 years, but not significant statistically. Based 
on the findings and observations, we have provided the appropriate counseling to the 
subjects. We have also made them aware about the importance of diabetes 
management and the precautions to be taken for its progression. 
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High prevalence of IGT and IFG validates that, there are chances of the pandemic 
trend in Gujarat, as eventually IGT and IFG may get converted into Diabetics in near 
future. These result needs urgent attention to develop a public awareness programme.  
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2. INTRODUCTION:  
 
Type 2 diabetes mellitus represents the final stage of a chronic and progressive 
syndrome representing a heterogeneous disorder caused by various combinations of 
insulin resistance and decreased pancreatic β-cell function caused by both genetic and 
acquired abnormalities (1-7). Diabetes is the most common metabolic disorder, which 
is still incurable even today.  
  
Currently, type 2 diabetes mellitus is diagnosed when the underlying metabolic 
abnormalities consisting of insulin resistance and decreased β-cell function cause 
elevation of plasma glucose above 126 mg/dl (7 mmol/L) in the fasting state and/or 
above 200 mg/dl (11.1 mmol/L) 120 min after a 75-g glucose load (8). Although 
defined on the basis of elevated plasma glucose levels, it is clear that diabetes is 
characterized by many associated abnormalities. More significantly, they predispose 
affected individuals to severe serious chronic problems. However, it is imperative for 
medical fraternity to identify “subclinical” diabetes to intercept the disease process. 
(9)  
 
However, the fact that many newly diagnosed type 2 diabetic subjects already suffer 
from so called “late complications of diabetes” at the time of diagnosis (10) indicates 
that the diagnosis may have been delayed and, in addition, that the prediabetic 
condition is harmful to human health and requires increased awareness by physicians 
and the general public. Thus, type 2 diabetes mellitus represents only the “tip of the 
iceberg” of long existing metabolic disturbances with deleterious effects on the 
vascular system, tissues, and organs. Consequently, urgent efforts are required to 
avoid the growing number of patients with this form of a “silently killing” metabolic 
disease. (11) 
 
Sixteen million individuals in the United States with type 2 diabetes mellitus and an 
additional 30–40 million with impaired glucose tolerance result in health care costs 
exceeding 100 billion dollars annually (12).Treatment is predominantly directed at 
microvascular and macrovascular complications (13). In type 1 diabetes mellitus the 
relationship between glycemic control and microvascular complications has been well 
established (14). The relationship between tight glycemic control and microvascular 
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disease in type 2 diabetes mellitus appears to be established in the recently completed 
United Kingdom Prospective Diabetes Study (15-16). India is a vast country with 
populations differing in racial admixtures as well as in social and cultural habits. It is 
likely that, the prevalence of non insulin dependent diabetes (type 2 diabetes) could 
also be different in various races due to genetic and environmental factors.  
 
An estimated 1 million new cases are identified each year in people aged ≥20 years 
(17). Two modern-day epidemics, HIV–AIDS and type 2 diabetes mellitus, have 
inspired impassioned calls for more effective interventions. In the 1980s, the rapid 
spread of HIV, with its associated severe acute illness and high mortality, prompted 
activist groups and others to call for the accelerated approval of medications that 
showed promise of efficacy. (18) Similarly, diabetes is recognized as a global health 
problem nowadays, and it has been projected that the number of diabetic patients are 
rising and will rise from an estimated 135 million in 1995 to 300 million in 2025. (19) 
 
Diabetes is more common in African Americans, Latinos, Native Americans, and 
Asian Americans/Pacific Islanders, as well as the aged population. This means they 
are also at increased risk for developing pre-diabetes. Prevalence of Type 2 diabetes is 
increasing globally as well as rapidly in India also. Asian Indians have an ethnic 
susceptibility to type II diabetes. (20) Type 2 diabetes constitutes about 85 to 95% of 
all diabetes in developed countries, and accounts for an even higher percentage in 
developing countries (21). There is substantial evidence that, it is epidemic in many 
developing and newly industrialized nations (22). 
 
Urban India is rapidly getting industrialized and is now one of the most common non-
communicable diseases globally. It has been demonstrated that, industrialization and 
modernization lead to sedentary lifestyle, obesity and higher risk of metabolic 
disorders (23-24).  
 
Prevalence of Diabetes in the world was 5.1 % in 2003 and by 2025 is around 6.5%. 
IGT prevalence in the world was 8.2 % in 2003 and to be 9.0% in 2025. (age group 
20-79 years). 
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Complications from diabetes, such as coronary artery and peripheral vascular disease, 
stroke, diabetic neuropathy, amputations, renal failure and blindness are resulting in 
increasing disability, reduced life expectancy and enormous health costs for virtually 
every society. Diabetes is certain to be one of the most challenging health problems in 
the 21stcentury (22).The country is already being dubbed as the “Diabetes Capital of 
the World.” 
Despite the morbidity and mortality associated with retinopathy, nephropathy, and 
neuropathy, cardiovascular disease remains the leading cause of death in type 2 
diabetes mellitus (25-26) consequently; the treatment of confounding risk factors of 
obesity, hypertension, and hyperlipidemia assumes major importance and must be 
coordinated with good glycemic control for reduction in total mortality in type 2 
diabetes mellitus (26-30).  
 
Currently up to 11 % of India’s urban population and 3 % of rural population above 
the age of 15 have diabetes. The WHO estimates the mortality from diabetes and heart 
disease cost India about 9450 billion rupees (210 billion $) and expected to increase to 
15075 billion rupees (335 billion $) in next 10 years (31).  
 
The economic growth of India is impressive with GDP clocking at higher rate during 
the last few years. This contributes further augmentation of purchasing power and 
consumer spending in the country. This economic growth has also seen the increasing 
westernisation of the Indian population. Dietary patterns are changing. Spending on 
food items are increasing and lifestyle becoming sedentary.Earlier, infectious and 
parasitic diseases were very common in India. However, significant medical 
advancement has helped to control the disease and this has started the new era of non 
communicable diseases like diabetes, obesity, hypertension, cancer and heart diseases 
(32).  
 
It has been reported that by year 2030, 46% of Indian population will live in cities. 
 
Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in 
natural history of diabetes mellitus. 
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The rising Impaired Glucose Tolerance (IGT) /Impaired Fasting Glucose (IFG) reflect 
not only the epidemic in India, but it is closely links to strong family history, social 
class and auxology. In fact, positive family history, changing socio-economic class, 
increasing waist circumference (WC), waist-hip ratio (WHR), weight and BMI are the 
most crucial drivers to rapidly rising diabetes in India (9). 
As discussed above, IGT and IFG are not equivalent metabolically, and it is therefore 
not surprising that there are differences in their prevalence and in the people 
categorized as having one or the other. A key issue is also the poor short-term 
repeatability of the OGTT. In most populations, IGT is more prevalent than IFG. 
Furthermore, there is some degree of overlap between the categories but the majority 
of people with IGT do not have IFG, and the majority with IFG does not have IGT. 
Thus, IFG and IGT identify substantially different segments of the population with 
impaired glucose regulation (33). 
The DECODE(34-36)and DECODA(37) studies, which include data from 13 
European and 11 Asian studies, respectively, reported that the mean two-hour plasma 
glucose concentration increased linearly with age, but a similar trend was not 
observed with FPG.  
The large increase in two-hour plasma glucose in the elderly resulted in the increase 
in the prevalence of undiagnosed diabetes.  
Individuals with IGT manifest abnormalities in insulin action and early insulin 
secretion similar to those seen in patients with type 2 diabetes. Furthermore 
progression of IGT to diabetes is characterised by dramatic decline in early insulin 
secretion. Acute Insulin secretary responses to intravenous glucose are lower in 
subject with IGT and they are high risk for developing diabetes. Prospectively low 
Acute Insulin Release (AIR) predicts development of diabetes in several populations. 
That’s why early insulin secretion is important for the rapid and efficient suppression 
of endogenous glucose production after meal (38). 
IFG was commoner in men than women in virtually all age groups, typically being 
1.5-3 times higher, but up to seven or eight times higher in Europeans aged 50-70 
years. But the prevalence of IGT was higher in women than men in all age groups 
except over the age of 60 in Asian populations and over the age of 80 in the European. 
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Finally, the prevalence of IGT tends to increase across all age groups, but that of IFG 
tends to plateau in middle age and in European men in particular falls in older age 
groups. Similar observations have been made in the USA, Denmark and Australia 
(39-42). 
Evidence from many prospective studies has indicated that subjects with IGT have 
markedly higher risk for the development of type 2 diabetes and for all cause and 
cardiovascular mortality than subjects with normal glucose. Many newly diagnosed 
IFG patients progress to diabetes in less than 3 years. Original IFG subjects converted 
at a rate of 5.56% per year after an average of 29 months (43).  
 
The WHO report had shown that diabetes was more common among middle-aged 
women in the developing countries, and this might be due to a higher proportion of 
women getting exposed to risk factors such as unhealthy diet, physical inactivity and 
central obesity (44). 
 
The major risk factors associated with diabetes in India were age and positive family 
history of diabetes. With the rising trend in the prevalence among the population, 
especially in the younger subjects, there is likelihood for further increase in the 
familial predisposition to the disease. Increasing prevalence of diabetes in younger 
age would imply a future escalation in the prevalence of diabetic complications also 
(44). 
 
It has been demonstrated that industrialization and modernization lead to sedentary 
lifestyle, obesity and higher risk of metabolic disorders. The risk variables associated 
with diabetes are almost similar in all nations, but its expressions and intensities vary 
widely between different races and countries (45). 
 
The prevalence of diabetes mellitus differs in all the states of India across the rural 
and urban area. This is because of the different dietary pattern, physical activity and 
mental status. 
 
In this study, we have analyzed the prevalence of prediabetes covering both Impaired 
Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT). We also tried to 
identify the major risk factors for the increase in this incidence.  
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3. OBJECTIVE: 
 
India is going to face a big challenge posed by the rising prevalence of diabetes and 
its complications unless steps are taken to implement the primary and secondary 
prevention in the diabetes. For this purpose it is quite essential to identify the risk 
factors for diabetes and for the vascular complications. The objectives of this study are 
following; 
 
 To determine the prevalence of Prediabetes (IFG and IGT) in the urban and rural 
population of Gujarat. 
 
 To also assess the attributable risk factors for the same in Gujarati population.
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4. REVIEW OF LITERATURE: 
4.1 Overview of Diabetes: 
Diabetes (diabetes mellitus) is a disorder of the human body, which is characterized 
by high blood sugar levels, a condition known as hyperglycemia. It is caused either by 
an inadequate secretion of the glucose-regulating hormone, insulin, or an inadequate 
response by the body’s cells to insulin.  
Progressive in nature, type 2 diabetes begins with peripheral insulin resistance and 
ends in complete loss of insulin secretion if the disease progresses through its entire 
natural history (46-48). Initially, pancreatic beta cells are able to compensate for 
insulin resistance by increasing basal and postprandial insulin secretion (49). 
 
In time, however, compensation fails as beta cells exhaust their capacity to react 
appropriately to rising glucose concentrations. A deterioration of glucose homeostasis 
ensues, and glucose intolerance develops (50). Left untreated, intolerance worsens, 
and the diabetic state is manifested. 
4.2 Types of Diabetes: 
Diabetes is classified into two categories; these are type 1 and type 2.  
Diabetes Mellitus Type 1 – Also called juvenile onset diabetes or Insulin-Dependent 
Diabetes Mellitus (IDDM), Type 1 diabetes is characterized by a decreased or 
outright absence of production of insulin. This is due to a disorder in the autoimmune 
response of the person, causing his own antibodies to attack the insulin producing 
cells in the pancreas.  
Diabetes Mellitus Type 2 – Also known as maturity onset diabetes, obesity-related 
diabetes, or Non-Insulin Dependent Diabetes Mellitus (NIDDM), Type 2 diabetes 
results from the inability of the body’s cells to respond to insulin. As the disease 
progresses, the production of insulin in the body decreases.  
Gestational Diabetes – This is often called Type 3 diabetes although the designation 
is rarely used in medical practice. Gestation diabetes occurs among women during 
pregnancy and is similar to Type 2 diabetes in that it is a result of the cell’s resistance 
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to insulin. The consequence is often abnormal increased fetal weight, increased 
surrounding amniotic fluid caused by increased fetal urination (called 
polyhydramnios), fetal jaundice and low blood sugars after delivery. On rare 
occasions, the condition has also been said to cause intra-uterine death. 
Irrespective of its type, diabetes represents an anomalous rise of glucose in a person's 
blood. This anomaly is as a result of the inadequate level of insulin or perhaps a 
misuse of it. If the suitable treatment is not given, this disease can be the cause of 
many severe complications (cardiac disease, amputations, blindness, and impotence).  
Although it normally occurs among older, inactive individuals, children and 
adolescents are increasingly identified, contributing to the growing pool of patients 
who require lifelong care (51–53).  
 
Initially, pancreatic beta cells are able to compensate for insulin resistance by 
increasing basal and postprandial insulin secretion (54).  
 
At this point in the disease, patients require therapy for glycemic control and have 
already developed an atherosclerotic burden. And hence, the strict attention is 
required. 
4.3 Signs of Diabetes: 
The onset of diabetes is varied, depending on its particular type. Most Type 2 diabetes 
cases have a slow onset, taking years before the signs start to appear. However, in 
Type 1 cases, particularly in children, the symptoms may appear rapidly, taking only 
months or even weeks.  
The most obvious signs of diabetes include the following: 
 Frequent thirst (polydipsia)  
 Constant urination (polyuria)  
 Rapid loss of weight  
 Unusual hunger  
 Obvious weakness and fatigue  
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4.4 Diagnosis of Diabetes: 
There are many methods by which diabetes is diagnosed, but doctors commonly use 
the following approaches: 
 Health screening  
 Detection of hyperglycemia  
 New signs and symptoms attributable to diabetes  
Diagnosis is often prompted with the onset of the symptoms. Patients often undergo a 
diabetes screening test, the particulars of which often vary according to circumstances 
and local policy. Some may be made to undergo random glucose testing, fasting 
glucose and insulin, or glucose two hours after ingestion of 75g of glucose. 
Sometimes, doctors diagnose the disease through a formal glucose tolerance test.  
For adults aged 40-50, healthcare givers recognize standard screening tests for 
diabetes with earlier screening tests for those with potential risk factors, such as 
obesity, family history of diabetes, and high risk ethnicity (Hispanic, American 
Indian, African, American, Pacific Island, and South Asian).LINICAL 
THERAPEUTICS® / VOL.UPPLEMENT B, 2003 
4.5 Pathophysiology of Type 2 Diabetes Mellitus: 
  
Type 2 diabetes mellitus is a heterogeneous disorder with varying prevalence among 
different ethnic groups. In the United States most affected populations are native 
Americans, particularly in the desert Southwest, Hispanic-Americans, and Asian-
Americans (55).  
 
Even in India, also the prevalence is highly variable in the several part of the country. 
Various studies have conducted to know the prevalence of the Diabetes in various part 
of the country. Recent population based studies showing the prevalence of type 2 
diabetes in different part of India (56). 
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Fig 1: Prevalence of Diabetes in various parts of India. 
(Adapted from Mohan V et al Diabetologia, 49:1175-8; 2006) 
 
The pathophysiology of type 2 diabetes mellitus is characterized by peripheral insulin 
resistance, impaired regulation of hepatic glucose production and declining β -cell 
function, eventually leading to β-cell failure. 
 
The primary events are believed to be an initial deficit in insulin secretion and, in 
many patients, relative insulin deficiency in association with peripheral insulin 
resistance (64-65).  
New Delhi 10.3 %(2003) 60 
Kashmir Valley 6.1 %(2000) 59 
Jaipur 8.6%(2003) 61 
Mumbai 9.3%(2001) 60 
Bengaluru 12.4 %(2001) 60 
Hyderabad 16.6%(2001) 60 
Kolkatta 11.7 %(2001) 60 
Guwahati 8.3%(2003) 58 
Ernakulam 19.5%(2006) 62 
Thriuvananthapuram 16.3%(1997) 57 
Chennai 13.5%(2001) 60 
               14.3%(2006) 63   
 
 
 
Page 14 of 107 
 
Insulin resistance and -cell dysfunction 
are core defects of type 2 diabetes
Insulin
resistance
Genetic susceptibility,
obesity, Western 
lifestyle
Type 2 diabetes
IR -celldysfunction
Rhodes CJ & White MF. Eur J Clin Invest 2002; 32 (Suppl. 3):3–13.  
 
Fig 2: Insulin resistance and β cell dysfunction 
 
4.5.1 The Role of β-cell in Insulin Resistance: 
 
The β-cell is critical in the maintenance of glucose tolerance and a marked decrease in 
β -cell function is clearly associated with the development of hyperglycemia in type 2 
diabetes.  β -Cell dysfunction is initially characterized by impairment in the first phase 
of insulin secretion during glucose stimulation and may antedate the onset of glucose 
intolerance in type 2 diabetes (66).  
 
Initiation of the insulin response depends upon the transmembranous transport of 
glucose and coupling of glucose to the glucose sensor. The glucose/glucose sensor 
complex then induces an increase in glucokinase by stabilizing the protein and 
impairing its degradation. The induction of glucokinase serves as the first step in 
linking intermediary metabolism with the insulin secretary apparatus. Glucose 
transport in β-cells of type 2 diabetes patients appears to be greatly reduced, thus 
shifting the control point for insulin secretion from glucokinase to the glucose 
transport system (67-68).  
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Later in the course of the disease, the second phase release of newly synthesized 
insulin is impaired, an effect that can be reversed, in part at least in some patients, by 
restoring strict control of glycemia. This secondary phenomenon, termed 
desensitization or β -cell glucotoxicity, is the result of a paradoxical inhibitory effect 
of glucose upon insulin release and may be attributable to the accumulation of 
glycogen within the β-cell as a result of sustained hyperglycemia (69).  
 
Other defects in β-cell function in type 2 diabetes mellitus include defective glucose 
potentiation in response to nonglucose insulin secretagogues, asynchronous insulin 
release, and a decreased conversion of proinsulin to insulin (70-71).  
 
Glucokinase is absent within the β-cell in some families with maturity onset diabetes 
of young (72). However, deficiencies of glucokinase have not been found in other 
forms of type 2 diabetes (73-74).  
 
In some early onset patients with type 2 diabetes (perhaps as many as 20%) there may 
be a deficiency in insulin secretion that may or may not be due to autoimmune 
destruction of the β -cell and is not due to a deficiency in the glucokinase gene. 
 
In the great majority of patients with type 2 diabetes (80%), the delay in immediate 
insulin response is accompanied by a secondary hypersecretory phase of insulin 
release as a result of either an inherited or acquired defect within the β-cell or a 
compensatory response to peripheral insulin resistance. Over a prolonged period of 
time, perhaps years, insulin secretion gradually declines, possibly as a result of intra 
islet accumulation of glucose intermediary metabolites (75).  
 
In view of the decline in β-cell mass, sulfonylureas appear to serve a diminishing role 
in the long term management of type 2 diabetes (76).  
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4.5.2 Insulin Resistance: 
Emanating from the prismatic demonstration by Yalow and Berson,the presence of 
hyperinsulinemia in type 2 diabetes, insulin resistance has been considered to play an 
integral role in the pathogenesis of the disease (77). 
 
Recent clinical reviews, however have questioned the primacy, specificity, and 
contribution of insulin resistance to the disease state (78-79).  
 
As chronic hyperinsulinemia inhibits both insulin secretion (80) and action (81), and 
hyperglycemia can impair both the insulin secretary response to glucose (82) as well 
as cellular insulin sensitivity (83-84), the precise relation between glucose and insulin 
level as a surrogate measure of insulin resistance has been questioned.  
 
Lean type 2 diabetic patients over 65 year of age have been found to be as insulin 
sensitive as their age matched nondiabetic controls (85).  
 
Moreover, in the majority of type 2 diabetic patients who are insulin resistant, obesity 
is almost invariably present (86-87).  
 
Additionally, insulin resistance is found in hypertension, hyperlipidemia, and 
ischemic heart disease, entities commonly found in association with diabetes (88-90) 
again raising the question as to whether insulin resistance results from different 
pathogenetic disease processes or is unique to the presence of type 2 diabetes (88, 91-
92).  
 
Prospective studies have demonstrated the presence of either insulin deficiency or 
insulin resistance before the onset of type 2 diabetes. Two studies have reported the 
presence of insulin resistance in nondiabetic relatives of diabetic patients at a time, 
when their glucose tolerance was still normal (93-94).  
 
Other studies in this high risk group have failed to demonstrate insulin resistance, and 
in the same group, impaired early phase insulin release and loss of normal oscillatory 
pattern of insulin release have been described (95-96).Based upon these divergent 
studies, it is still impossible to dissociate insulin resistance from insulin deficiency in 
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the pathogenesis of type 2 diabetes. However, both entities unequivocally contribute 
to the fully established disease. 
4.5.3 Metabolic abnormalities associated with Insulin Resistance: (97) 
            Increase        Decrease 
Small dense low density lipoprotein Triglyceride elimination 
Central body fat High density lipoprotein 
Free fatty acids Vasodilatory response 
Triglyceride synthesis  
Insulin  
Proinsulin  
Plasminogen Activator inhibitor-1  
Sympathomimetic activity  
Sodium retention  
Blood pressure  
 
Table: 1 Metabolic abnormalities associated with insulin resistance. 
 
 
Fig 3: Pathology of diabetes 
Understanding the importance of insulin sensitivity in modulating β-cell function has 
demonstrated that the β-cell is capable of dramatically increasing insulin release in 
response to increased secretary demand. In individuals, who are at increased risk of 
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developing type 2 diabetes, this adaptive response is inadequate and results in 
deteriorating glucose tolerance. 
 
In fact, even within the normal range of fasting glucose, β-cell function declines as 
plasma glucose increases. There has been a resurgence of interest in changes in β-cell 
morphology in type 2 diabetes. It is clear that the numbers of β-cells are decreased in 
the disease, and this is in part due to the deposition of islet amyloid. In addition to 
reductions in β-cell mass, functional changes in secretary function also occur 
independently.  
 
In humans acute elevations in free fatty acids are associated with decreased β-cell 
function. Thus, the reduced insulin release observed in type 2 diabetes and in high-
risk states is clearly multifactorial, and is related to both genetics and environmental 
changes (98).  
 
4.6 Risk factors of Diabetes: 
 
Type 2 diabetes is known as a metabolic cum vascular disease. The American Heart 
Association has recently stated that “From the point of view of cardiovascular 
medicine, it may be appropriate to say diabetes is a cardiovascular disease”. It is well 
known that diabetic vascular disease is not just limited to the macro vasculature, but 
also affect the microcirculation with devastating results, like Neuropathy, 
Nephropathy and Retinopathy. 
Following are at higher risk factors for diabetes: 
 Age greater than 45 years 
 Diabetes during a previous pregnancy 
 Excess body weight (especially around the waist) 
 Family history of diabetes 
 Given birth to a baby weighing more than 4.5 kg                                                                               
 HDL cholesterol under 35 mg/dL 
 High blood levels of triglycerides(250 mg/dL or more) 
 High blood pressure (greater than or equal to 140/90 mmHg) 
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 Impaired glucose tolerance 
 Low activity level (exercising less than 3 times a week) 
 Metabolic syndrome 
 Polycystic ovarian syndrome 
 A condition called acanthosis nigricans, which causes dark, thickened skin around 
the neck or armpits 
 
4.7 Management of Diabetes: 
 
Because more than 75% of adult patients with type 2 diabetes die of macro vascular 
events such as myocardial infarction and stroke,(99) afflicted patients require 
comprehensive management to control their diabetes as well as any other metabolic 
disorders that contribute to cardiovascular risk and disease related morbidity and 
mortality. 
 
4.7.1 Type 2 Diabetes Treatment Goals: 
The goal of treatment in type 2 diabetes is to keep blood sugar levels at normal or 
near normal levels. Careful control of blood sugars can help to prevent the long-term 
effects of poorly controlled blood sugar (diabetic complications of the eye, kidney, 
and cardiovascular system). 
In people with type 2 diabetes, home blood sugar testing might be recommended, 
especially in those who take oral diabetes medicines or insulin shots. Home blood 
sugar testing is not usually necessary for people who are diet controlled.  
A normal fasting blood sugar is less than 100 mg/dL(5.6 mmol/L), although some 
people will have a different goal.  
Blood sugar control can also be estimated with a blood test called A1C. The A1C 
blood test measures your average blood sugar level during the past two to three 
months. The goal A1C for most people with type 2 diabetes is 7 percent or less, which 
corresponds to an average blood sugar of 150 mg/dL (8.3 mmol/L).  
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Person’s average blood sugar (150 mg/dl or 8.3 mmol/L) is higher than their fasting 
blood sugar goal (100 mg/dL or 5.6 mmol/L) for several reasons. 
 Blood sugar goes up after eating 
 How much and how fast your blood sugar goes up depends on the type and 
amount of food you eat at a particular meal 
 The amount your blood sugar goes up also depends on what diabetes treatment(s) 
you use and your activity level 
The most common long-term complication of type 2 diabetes is cardiovascular (heart) 
disease, which can lead to heart attack, chest pain, stroke, and even death. People with 
type 2 diabetes have twice the risk of heart disease as those without diabetes. 
However, you can substantially lower your risk of cardiovascular disease by: 
 Quitting smoking 
 Managing high blood pressure and high cholesterol with diet, exercise, and 
medicines 
 Taking a low-dose aspirin every day, if indicated 
4.7.2 Type 2 Diabetes Medicines: 
A number of oral medicines are available for treatment of type 2 diabetes as given 
below: 
Metformin - Most people who are newly diagnosed with type 2 diabetes will 
immediately put on a medicine called Metformin. Metformin improves how your 
body responds to insulin to reduce high blood sugar levels. 
Common side effects of metformin include nausea, diarrhea and flatulence. These are 
usually not severe, especially if you take metformin along with food. 
Patients with certain types of kidney, liver, and heart disease, and those who drink 
alcohol excessively should not take metformin.  
If the blood sugar levels are still high after two to three months, but your A1C is close 
to the goal (between 7 and 8.5 percent), a second medicine might be added. The best 
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second medicine depends upon individual factors, including the person's weight, other 
medical problems, and preferences regarding use of injections.  
The following are general recommendations: 
 The most commonly recommended second medicine is a short acting 
sulfonylurea, such as glipizide. 
 A thiazolidinedione, such as pioglitazone, is an alternative to sulfonylureas, but 
only for people who are not at increased risk of heart failure or bone fracture. 
 A GLP-agonist, such as Exenatide, is an option for patients who are overweight 
and who want to avoid developing low blood sugar.  
 A meglitinide, such as Repaglinide, is an option for people who cannot take a 
sulfonylurea or prefer to avoid injections.  
Sulfonylureas — Sulfonylureas have been used to treat type 2 diabetes for many 
years. They work by increasing the amount of insulin what your body makes, and can 
lower blood sugar levels by approximately 20 percent. However, they stop working 
over time. 
Sulfonylureas are generally used, if metformin does not adequately control blood 
sugar levels when taken alone. One should not take a sulfonylurea if he/she is allergic 
to sulfa drugs. 
If you take a sulfonylurea, you can develop low blood sugar, known as hypoglycemia. 
Low blood sugar symptoms can include: 
 Sweating 
 Shaking 
 Feeling hungry 
 Feeling anxious 
Low blood sugar must be treated quickly by eating 10 to 15 grams of fast-acting 
carbohydrate (eg, fruit juice, hard candy, glucose tablets).  
Insulin - In the past, insulin treatment was reserved for patients with type 2 diabetes 
whose blood sugars were not controlled with oral medicines and lifestyle changes. 
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However, there is increasing evidence that using insulin at earlier stages may improve 
overall diabetes control and help to preserve the pancreas's ability to make insulin. 
Insulin injections may be used as a first-line treatment in some people with type 2 
diabetes, or it can be added to or substituted for oral medicines.  
Thiazolidinediones - This class of medicines includes Pioglitazone, which work to 
lower blood sugar levels by increasing the body's sensitivity to insulin.  
Common side effects of thiazolidinediones include: 
 Weight gain and swelling of the feet and ankles. 
 A small but serious increased risk of developing or worsening heart failure. 
People who take thiazolidinediones should monitor for swelling. 
 A small increased risk of bone fractures 
GLP-agonists - The GLP-agonists, Exenatide and Liraglutide, are injectable 
medicines. They are not a first line treatment, but might be considered for people 
whose blood sugar is not controlled on the highest dose of one or two oral 
medicines.They may be especially helpful for overweight patients, who are gaining 
weight on oral medicine.  
GLP-agonists do not usually cause low blood sugar. They promote weight loss, but 
can also cause bothersome side effects, including nausea, vomiting, and diarrhea. 
Pancreatitis has been reported rarely in patients taking GLP-agonists, but it is not 
known if the drugs caused the pancreatitis. You should stop taking exenatide or 
liraglutide, if you develop severe abdominal pain. Exenatide should not be used in 
patients with abnormal kidney function.  
DPP-IV Inhibitors - This class of medicines includes Sitagliptin, Saxagliptin, and 
Vildagliptin. They lower blood sugar levels by increasing insulin release from the 
pancreas in response to a meal. They are not a first-line treatment, but they can be 
given alone in patients who can’t tolerate the first-line medicines (metformin, 
sulfonylureas), or they can be given with other oral medicines if blood sugars are still 
higher than goal. These medicines do not cause hypoglycemia or changes in body 
weight. However, they may cause some nausea and diarrhea. There have been rare 
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reports of pancreatitis and skin reactions. DPP-IV inhibitors are expensive, and the 
long-term risks and benefits are unknown. 
Meglitinides - Meglitinides include Repaglinide and Nateglinide. They work to lower 
blood sugar levels, similar to the sulfonylureas, and might be recommended in people 
who are allergic to sulfa-based drugs.  
Alpha-glucosidase inhibitors-which include Acarbose and Miglitol, work by 
interfering with the absorption of carbohydrates in the intestines. This helps to lower 
blood sugar levels, but not as well as metformin or the sulfonylureas. They can be 
combined with other medicines if the first medicine does not lower blood sugar levels 
enough. 
The main side effects of alpha-glycosidase inhibitors are gas (flatulence), diarrhea, 
and abdominal pain; starting with a low dose may minimize these side effects. The 
medicine is usually taken three times per day with the first bite of each meal (100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 24 of 107 
5. COMMON MYTHS AND FACTS ABOUT DIABETES: 
 
Myth 1: The greatest misconception regarding diabetes is that, it is a disease of 
affluence and rich. 
 
Fact: This is totally untrue, as the disease affects rich as well as poor alike and seen in 
all strata of the population. 
 
Myth 2: The belief is that it is contagious. 
 
Fact: It is untrue as the disease is not transmitted by any germs but runs in families as 
it is transmitted to the offspring by genetic transmission.  
 
Myth 3: It is believed that once diabetes is controlled one can take liberties regarding 
diet as medicines are controlling diabetes. 
 
Fact: Diet and exercise is cornerstone in diabetes. 
 
Myth 4: Once the Insulin is started in patients it becomes lifelong treatment. 
 
Fact: This is especially not true with diabetes. 
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6. PREDIABETES: 
 
Pre-diabetes (comprise of IFG and IGT) is the state that occurs when a person's blood 
glucose levels are higher than normal but not high enough for a diagnosis of diabetes.  
 
The terms IFG and IGT refer to an intermediate metabolic stage between normal 
glucose and diabetes. The concept of IFG was introduced by Charles et al. to refer at 
fasting plasma glucose levels > 6.1 and < 7.8 mmol/L (101).  
 
Impaired glucose tolerance is a more advanced stage of alteration in the glucose 
metabolism than impaired fasting glucose (102). 
 
These fasting plasma glucose limits correspond to the level above which acute phase 
insulin secretion is lost in response to intravenous administration of glucose (103).  
 
About 11 percent of people with pre-diabetes in the Diabetes Prevention Program 
standard or control group developed type 2 diabetes each year during the average 
three years of follow-up. Other studies show, that many people with pre-diabetes 
develop type 2 diabetes in 10 years. 
 
Recently, the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus (1999) proposed a reduction in both upper and lower fasting glucose values 
for diagnosis of IFG to correspond at the new diagnosis criteria for diabetes (104-
106). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: Blood glucose ranges in IFG and IGT patients 
                 FPG                 OGTT 
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However, recent reports have shown a lack of agreement between the 2-h post glucose 
category of IGT and the fasting glucose category of IFG among subjects of different 
ethnic populations. 
 
Among US adults, 40-74 years of age, 15.6 percent (14.9 million) have IGT, and 9.7 
percent (9.6 million) have IFG (107-109). 
Indeed, an analysis on the 7-year follow-up Funagata Diabetes Study showed that IGT 
is a risk factor for cardiovascular disease, whereas IFG is not (110). 
 
Moreover, longitudinal population-based studies have demonstrated a higher 
sensitivity of IGT over IFG for predicting the progression to type 2 diabetes (111).  
 
People with pre-diabetes are at higher risk of cardiovascular diseases. People with 
pre-diabetes have a 1.5-fold risk of cardiovascular disease compared to people with 
normal blood glucose. People with diabetes have 2 to 4 fold increased risk of 
cardiovascular diseases. 
People who are overweight and age 45 or older, they should be checked for pre-
diabetes during their next routine medical visit. If their weight is normal and they are 
over age 45, they should ask their doctor during a routine office visit, if testing is 
appropriate.  
For adults younger than 45 and overweight, your doctor may recommend testing if 
you have any other risk factors for diabetes or pre-diabetes. These include high blood 
pressure, low HDL cholesterol and high triglycerides, a family history of diabetes, a 
history of gestational diabetes or giving birth to a baby weighing more than 4 kg (~ 9 
pounds) or belonging to an ethnic or minority group at high risk for diabetes. 
 
To maintain serum glucose under 7.8 mmol/L, subjects with IFG show a significant 
hyperinsulinemia post glucose load, whereas the IGT subjects exhibit low insulin 
secretion unable to maintain the serum glucose within the normal referenced range 
values, findings that suggest different stages of impaired insulin secretion. 
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On the same way, our findings show that IGT is a more advanced stage of alteration 
in the glucose metabolism than the IFG. On the basis of this statement, the lack of 
concordance between IFG and IGT criteria that has been reported (112-116). 
 
IFG and IGT are metabolically distinct disorders with limited overlap, among those 
who had IFG and/or IGT, 16 percent had both IFG and IGT, 23 percent had IFG alone 
and 60 percent had IGT alone (117).  
 
IGT is a common condition that greatly increases risk for the subsequent development 
of type 2 diabetes. Individuals with IGT manifest abnormalities in both insulin action 
and early insulin secretion similar to those seen in patients with type 2 diabetes. These 
abnormalities not only precede diabetes, they predict it as well. Furthermore, the 
progression from IGT to diabetes is characterized by a dramatic decline in early 
insulin secretion. It is now evident that early insulin secretion plays an important role 
in the rapid and efficient suppression of endogenous glucose production following a 
meal. Loss of early insulin secretion initially leads to postprandial hyperglycemia 
which, as the disease progresses, worsens to clinical hyperglycemia.  
 
Studies have shown that people with pre-diabetes can prevent or delay the 
development of type 2 diabetes by up to 58 percent through changes to their lifestyle 
that include modest weight loss and regular exercise. The expert panel recommends, 
that people with pre-diabetes reduce their weight by 5-10 percent and participate in 
some type of modest physical activity for 30 minutes daily. For some people with pre-
diabetes, intervening early can actually turn back the clock and return elevated blood 
glucose levels to the normal range. 
Symptoms of Insulin Resistance and Pre-diabetes: 
 
Insulin resistance and pre-diabetes usually have no symptoms. If you have a severe 
form of insulin resistance, you may get dark patches of skin, usually on the back of 
your neck. Sometimes people get a dark ring around their neck. Other possible sites 
for these dark patches include elbows, knees, knuckles, and armpits. This condition is 
called acanthosis nigricans. 
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6.1 Pathogenesis of Prediabetes:  
The progression from normal glucose tolerance to type 2 diabetes is characterized by 
dual defects that include insulin resistance and an insulin secretary defect caused by 
beta-cell dysfunction. 
 
 
 
Fig 5: Etiologic sequence for the development of type 2 diabetes. 
 
Insulin resistance is characterized by decreased tissue sensitivity to insulin and 
marked compensatory hyperinsulinemia. Initially, plasma glucose levels are 
maintained in the normal range. In patients, who will eventually develop diabetes, 
there is a decline in beta-cell secretary capacity.  
 
Insulin resistance precedes the onset of type 2 diabetes mellitus by several years. 
During this time a prediabetic state of compensated hyperinsulinemia exists 
characterized by impaired glucose tolerance and associated with dyslipidemias and 
other metabolic abnormalities of the insulin resistance state. 
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The existence of long history of an atherogenic, prediabetic state emphasizes the 
importance of long term strategy for primary prevention of type 2 diabetes. 
 
The first glucose abnormality that is detected is a rise in the postprandial glucose 
levels because of reduced first-phase insulin secretion. With time, further decline in 
beta cell function leads to elevation of the fasting glucose levels. Eventually, diabetes 
occurs, with more insulin secretary loss. 
 
6.2 Focus on Prevention: 
IGT is the first easily identifiable step in the pathophysiology of type 2 diabetes 
mellitus. It is associated with high risk for type 2 diabetes mellitus and subsequent 
vascular morbidity and mortality. It is currently unknown, whether treating IGT will 
reduce the incidence of macro vascular complications, as studies addressing this issue 
have yet to be conducted. Therefore, the main reason to identify and treat IGT is to 
prevent or delay the onset of type 2 diabetes mellitus.  
Recent studies of patients with IGT have shown success for lifestyle interventions in 
delaying or preventing the development of diabetes (118-120).  
 
There is strong evidence that a structured programme of diet and exercise can reduce 
the risk of progression to type 2 diabetes in patients with IGT. Patients with IFG and 
IGT should be advised on the benefits of modest weight loss, good dietary habits and 
regular physical activity. 
IGT is characterized by an increase in postprandial glucose levels, which is 
considered the earliest metabolic abnormality in type 2 diabetes mellitus. It is one of a 
series of risk factors for CVD (hypertension, high triglyceride levels, low high-density 
lipoprotein-cholesterol and central obesity), known as the metabolic syndrome. The 
different factors making up this syndrome are intimately related. An impaired lipid 
profile can contribute to insulin resistance, as IGT may play a pathogenic role on 
other cardiovascular risk factors. 
 
Macronutrients (MNT) is an integral component of diabetes prevention, management, 
and self-management education. In addition to its role in preventing and controlling 
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diabetes, ADA recognizes the importance of nutrition as an essential component of an 
overall healthy lifestyle. 
 
Clinical trials/outcome studies of MNT have reported decreases in A1C at 3–6 months 
ranging from 0.25% to 2.9% with higher reductions seen in type 2 diabetes of shorter 
duration. 
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7. DIABETES SELF-MANAGEMENT EDUCATION (DSME): 
People with diabetes should receive diabetes self-management education (DSME) 
according to national standards when their diabetes is diagnosed and as needed 
thereafter. Effective self-management and quality of life are the key outcomes of 
DSME and should be measured and monitored as part of care (121–126). 
DSME is an essential element of diabetes care and national standards for DSME are 
based on evidence for its benefits.  
 
Education helps people with diabetes initiate effective self-management and cope 
with diabetes when they are first diagnosed. Ongoing DSME and support also help 
people with diabetes maintain effective self-management throughout a lifetime of 
diabetes as they face new challenges and treatment advances become available.DSME 
helps patients optimize metabolic control, prevent and manage complications, and 
maximize quality of life in a cost-effective manner (127). 
 
DSME is the ongoing process of facilitating the knowledge, skill, and ability 
necessary for diabetes self-care. This process incorporates the needs, goals, and life 
experiences of the person with diabetes. The overall objectives of DSME are to 
support informed decision-making, self-care behaviors, problem-solving, and active 
collaboration with the health care team to improve clinical outcomes, health status, 
and quality of life in a cost-effective manner (128). 
 
Current best practice of DSME is a skills-based approach that focuses on helping 
those with diabetes to make informed self-management choices.  
 
 Individuals who have prediabetes or diabetes should receive individualized 
medical nutrition therapy (MNT) as needed to achieve treatment goals.  
 In overweight and obese insulin-resistant individuals, modest weight loss has been 
shown to reduce insulin resistance. Thus, weight loss is recommended for all 
overweight or obese individuals who have or are at risk for diabetes.  
 For weight loss, either low-carbohydrate, low-fat calorie-restricted, or 
Mediterranean diets may be effective in the short-term (up to 2 years). 
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 For patients on low-carbohydrate diets, monitor lipid profiles, renal function, and 
protein intake (in those with nephropathy), and adjust hypoglycemic therapy as 
needed.  
 Physical activity and behavior modification are important components of weight 
loss programs and are most helpful in maintenance of weight loss.  
 Among individuals at high risk for developing type 2 diabetes, structured 
programs that emphasize lifestyle changes that include moderate weight loss (7% 
body weight) and regular physical activity (150 min/week), with dietary strategies 
including reduced calories and reduced intake of dietary fat, can reduce the risk 
for developing diabetes and are therefore recommended.  
 Individuals at high risk for type 2 diabetes should be encouraged to achieve the 
U.S. Department of Agriculture (USDA) recommendation for dietary fiber (14 g 
fiber/1,000 kcal) and foods containing whole grains (one-half of grain intake) 
(121-126). 
7.1 Macronutrients in Diabetes Management: 
 The best mix of carbohydrate, protein, and fat may be adjusted to meet the 
metabolic goals and individual preferences of the person with diabetes.  
 For individuals with diabetes, the use of the glycemic index and glycemic load 
may provide a modest additional benefit for glycemic control over that observed 
when total carbohydrate is considered alone.  
 Saturated fat intake should be <7% of total calories. 
 Reducing intake of trans fat lowers LDL cholesterol and increases HDL 
cholesterol. 
 Routine supplementation with antioxidants, such as vitamins E and C and 
carotene, is not advised because of lack of evidence of efficacy and concern 
related to long-term safety.  
 Individualized meal planning should include optimization of food choices to meet 
recommended dietary allowance (RDA)/dietary reference intake (DRI) for all 
micronutrients.  
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8. PHARMACOECONOMICS OF DIABETES: 
The average cost of Diabetes management in India is around INR 20000/- per 
annum.In this, ambulatory care constitutes 65% of cost, while the hospitalization cost 
is 35%. Cost of medications is 31% of which specific diabetes drug costs are only 
17%. Ambulatory care including monitoring and doctor visits constitute 34% of costs. 
 
Description Cost(INR) 
Clinician Visit 853.00 
Monitoring and Laboratory expenses 1609.00 
Treatment cost 2262.00 
Hospitalization  2434.00 
Mean total direct cost 7158.00 
Mean indirect cost 12756.00 
Total estimated annual cost  19914.00 
 
Table: 2 Cost of Diabetes management in India 
 
8.1. Factors influencing Costs of Care: 
 
8.1.1. Late vs Early Diagnosis: 
 
Diabetes is often diagnosed late, perhaps too late. 50% of people with diabetes even in 
developed countries have complications at diagnosis. Untreated or improperly 
managed diabetes leads to serious and often life-threatening complications. 
 
Complications requiring multiple therapies and prolonged hospitalization are 
responsible for most of the diabetes-related direct costs. Among people with diabetes 
who are hospitalized, the average annual direct costs are more than double those for 
people with diabetes who are not hospitalized. Complications are also responsible for 
indirect costs in terms of productivity loss and absenteeism. 
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8.1.2 Education: 
Many socio-economic factors affect the time of diagnosis and thus the outcome of 
diabetes. Consequently they also affect the costs. The level of education appears to be 
important. 
 
Diagnosis can be delayed by 3-7 years in the less-educated and uneducated sections of 
the population. The age of diagnosis was directly related to the level of education: 
college-educated people were on average diagnosed seven years before people with 
no literacy. 
 
Despite a longer average duration of diabetes, those with a college education had a 
considerably lower rate of diabetes complications (45% complication-free) compared 
with people with low or no literacy (20% complication-free). 
 
8.1.3. Unemployment: 
 
Type 2 diabetes produces few symptoms and acutely is not life threatening. Often, 
weakness and tiredness are the only manifestations of the condition. While it is 
common for inactive unemployed people to ignore these symptoms (consciously or 
otherwise), those who are working are more likely to notice the signs as these 
influence the capacity to work. In the CODI study, compared to working people in 
urban areas, people in lower-income groups were diagnosed on average 4 years later 
as were people living in remote rural areas. People who are aware of diabetes before 
diagnosis or those with a family member with diabetes may be diagnosed earlier. 
 
8.1.4 Complications: 
 
The factors that influence delay in diagnosis also determine the rate of complications. 
Place of residence seems to play an indirect role: people with diabetes living in the 
semiurban or rural areas have higher rates of complications; despite less duration of 
diabetes; than those in urban settings. This would appear to reflect delayed diagnosis 
and the availability of less-than-optimum or indeed the total lack of care. 
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A similar trend is noted with regard to employment and socioeconomic status. 
Employed and working people with diabetes have fewer complications compared to 
those not working or those in rural areas engaged in agricultural labor. Among people 
with similar diabetes duration, larger proportions from the higher socio-economic 
strata are free of or have fewer diabetes complications (54% complication free; 8% 
with three complications), compared to the lower socioeconomic group (22% 
complication free; 26% with three complications).As might be expected, education 
appears to play a role in the development of diabetes complications. 
 
For people with a similar duration of diabetes, 45% of those who finished higher 
education had no complications, compared to 20% for the no-literacy group. While 
awareness alone cannot overcome the socioeconomic barriers to health, within the 
same socio-economic groups, people who are aware of the problem suffer fewer 
complications than those who are not aware. Similar findings have been reported from 
the USA. 
 
While the average annual direct cost for out-patient care for all people with diabetes 
was 4724 INR, the cost of care for those without complications was 18% lower, but 
48% higher for those with three or more complications. As with ambulatory care, the 
cost of hospitalization increased with the number of complications. 
 
8.2. Conclusions: 
Uneducated, unemployed people with diabetes who cannot afford or do not have 
access to even minimum healthcare facilities especially those living in semi-urban or 
rural areas  are likely to be diagnosed late. They are at increased risk of developing 
diabetes related complications due to delays in diagnosis and/or improper treatment. 
 
Effective treatment of diabetes is not costly; however, in both human and economic 
terms, not treating the condition is extremely costly. 
 
Also due to current rise in inflation and raising the cost of medications, it is 
anticipated that the cost of therapy will rise exponentially. The present cost of INR 
20000/-(128-131) may be touch to INR 25,000 – INR 30,000.  
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9. MATERIALS AND METHODS: 
The present cross functional study was carried out in various locations of Gujarat. We 
followed the American Diabetic Association (ADA) criteria for defining the IFG and 
IGT. 
 
Impaired Fasting Glucose (IFG) was defined as a fasting plasma glucose value of100-  
125 mg/dl (5.6-6.9 mmol/L) in the absence of a previous diagnosis of diabetes (132). 
 
Impaired Glucose Tolerance (IGT) was defined as a plasma glucose concentration of 
140-200 mg/dl (7.8 to 11.0 mmol/L) two hours after oral administration 75 gm of 
glucose in subjects, whose plasma glucose concentration after overnight fasting was 
less than 140 mg/dl (132). 
 
9.1 Study documents preparation:  
 
Protocol, ICF and CRF were prepared in consultation with the experts, Dr.N.R.Sheth 
and Dr.Bhagirath Solanki. In the process Declaration of Helsinki principle was 
followed.After the preparation, quality check was performed. The required copies 
were prepared and submitted to the ethics committee of B.J.Medical College and Civil  
Hospital, Ahmedabad for its review.An Informed consent form was prepared as per 
the regulatory requirement.(Appendix-I) 
 
9.2 Case Record Form: 
 
A survey questionnaire was administered to all the participating subjects to collect the 
detailed information. (Appendix-II) 
 
9.2.1 Demographic Details: 
 
Following demographic details were collected from all the participating subjects.  
a) Age b) Sex c) Height d) Weight e) BMI f) Waist to Hip ratio g) Systolic Blood 
pressure h) Diastolic Blood pressure 
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9.2.2 Inclusion & Exclusion Criteria: 
Inclusion Criteria: 
 Men and Women of age > 20 years 
 Having family history of Diabetes mellitus 
 Subjects who are willing to participate in the study 
 
Exclusion Criteria: 
 Patients who are diabetics and pursuing diet, exercise and Oral hypoglycemic 
agents and Insulin also. 
 
We have focused on the family members of diabetic patients because they are very 
much keen to undergo risk stratification and they comply with the camp activities. 
 
To get around 1650 eligible subjects, approximately 1700 individuals (considering the 
drop out ratio of around 15%, for any reasons) more than > 20 years of age were 
screened from the different areas of Gujarat. We also ensured that, we get the equal 
distribution from all the socio economic class, education class, field workers and 
office workers.  
9.2.3 Laboratory Investigations: 
Following laboratory investigations were performed for all the individuals at the 
central laboratory. A qualified and trained doctor/phlebotomist collected the blood 
samples. 
 
a. Fasting blood glucose 
b. 2 h Blood Glucose 
c. Total cholesterol 
d. Serum Triglycerides 
e. Serum HDL cholesterol 
f. Serum LDL cholesterol 
 
9.3. Ethics Committee Approval: The study documents were approved by the ethics 
committee of B.J Medical College and Civil Hospital, Ahmedabad. (Appendix-III) 
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9.4 Methodology followed during the Screening: 
 
9.4.1. Activities carried out before camps (2 weeks before): 
 
 Meeting with Local Lions Club/Society/Community group/School management. 
 Meeting with Local Family Physicians 
 Registration of subjects 
 
9.4.2. Activities carried out during Camps: 
 
 Validate the registration of subjects 
 Obtain the consent from subjects 
 Collect the blood for investigations (Fasting stage) 
 Administration of 75 gm Glucose dissolved in water  
 Meet the physician (for physical examination) 
 Collection of all demographic details in the CRF 
 After 2 hours blood collection 
 At the end, awareness was created in community about, How to Prevent Diabetes?  
 
9.4.2.1 Anthropometric Measurement: 
 
Body weight was measured (to the nearest 100 gm) with the subject standing still on 
weighing scale and weight equally distributed on each leg. Subjects were instructed to 
wear minimum outerwear and no footwear, while their weight was being measured.  
 
Height was measured using a nonstretchable tape (to the nearest 0.1 cm) with the 
subject in an erect position against a vertical surface and the head positioned so that 
the top of the external auditory meatus was in the level with the inferior margin of the 
body orbit.  
 
Body mass index was calculated by dividing the weight (in kilograms) with the square 
of height (in meters). 
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Waist circumference (to the nearest 0.1 cm) was measured using a tailor’s tape at a 
point mid way between tip of iliac crest and last costal margin in the back and at 
umbilicus in the front.  
 
After each subject had been seated for 5 min, blood pressure was measured twice to 
the nearest 2 mm Hg from the left arm of the participant using a standard 
sphygmomanometer. The average of the two measurements was used for all analyses. 
Diastolic blood pressure (DBP) was recorded at the fifth Korotkoff sound. 
 
The physicians completed the interview questionnaire, which included questions 
about past medical history, family history of diabetes, history of medical treatment, 
smoking habits, occupation and education. Smoking status included current smoker 
and non-smoker.  
 
9.4.2.2 Laboratory Analysis: 
 
After 10–12 hr of an overnight fast, each subject voided, and then the fasting blood 
sample was collected. A 75 gm anhydrous glucose dissolved in 250 ml of water was 
given orally over the course of 5 min and a second blood sample was drawn  exactly 2 
h later for glucose estimation. Blood for glucose determination was collected into 
tubes containing fluoride and EDTA.Through out the study only one technician was 
allocated to avoid interpersonal error. 
 
These blood samples were immediately centrifuged and processed further. Lipid 
profile samples were analyzed by Erba EM 360 (Germany). 
 
9.4.3 Recruitment Status: 
 
In this randomly selected study, we could manage to collect the data for 1652 subjects 
in the eleven camps. The details of conducted screening camps are as follows; 
 
 
 
 
Page 40 of 107 
228Bayad, Dist:Sabarkantha
192Salal, Dist:Sabarkantha
152Modasa-2  Dist:Sabarkantha
153Modasa-1  Dist:Sabarkantha
097Dhansuara,  Dist:Sabarkantha
154Ubharan,  Dist:Sabarkantha
096Lunawada Dist: Panchmahal
099Munjka & Rajkot
124Meghaninagar,Ahmedabad
204Bapunagar,Ahmedabad
153Sthapatya
Apt,Gurukul,Ahmedabad
 
Fig 6: Location of the camps and recruitment status 
Overall 12 screening camps were conducted at various Rural and Urban areas of 
Gujarat. 
 
Sr.No Place of Camp Area Date of 
Camp 
No. of 
Subjects
1. Lunawada, Dist: Panchmahal Rural 17/05/2007 096 
2. Sthapatya 
Apt,Gurukul,Ahmedabad 
Urban 20/05/2007 153 
3. Bayad,Dist:Sabarkantha Rural 27/05/2007 228 
4. Ubharan, Dist:Sabarkantha Rural 03/06/2007 154 
5. Dhansuara, Dist:Sabarkantha Rural 10/06/2007 097 
6. Modasa-1, Dist:Sabarkantha Urban 07/10/2007 153 
7. Modasa-2, Dist:Sabarkantha Urban 14/10/2007 152 
8. Salal,Dist:Sabarkantha Rural 17/11/2007 192 
9. Bapunagar,Ahmedabad Urban 09/12/2007 204 
10. Meghaninagar,Ahmedabad Urban 23/12/2007 124 
11. Munjka, Dist:Rajkot Rural  19/03/2008 050 
12. Rajkot Urban 19/03/2008 049 
                                      Total 1652 
 
Table: 3 Recruitment status during camps. 
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9.4.3.1 Schedule of Events: 
 
 
 
Fig 7: Schedule of events of the trial. 
 
All the subjects were assessed for the Inclusion and Exclusion criteria as per the 
Protocol. No subjects were enrolled inadvertently and by practicising that highest 
quality standard was maintained. 
 
 
Collection of Fasting blood glucose 
Ingestion of 75 gm Glucose 
Anthropological 
measurement: Height, 
Weight, Waist, Hip 
After 2 hours of Glucose intake, blood collection 
for GTT. 
Subject gives the 
ICF
Collection of demographic details 
Counseling by Investigators 
based on the history. 
Delivery of laboratory reports 
with remarks, if any. 
 
 
 
Page 42 of 107 
9.4.4 Activities carried out after Camps: 
 Discussion with Dr. N.R. Sheth 
 Issue resolution and learning for the other camps 
 Data entry 
 Data validation and QC checks of the data 
 Data cleaning & analysis 
 
9.5 Methodology followed during Data entry: 
 
During each camp, data in the CRFs were collected by trained team members. The 
time available between fasting glucose collection and 2 h post glucose collection was 
utilised to gather complete and appropriate demographic information. Each CRF was 
also checked for its completeness and correctness. Each team members was also 
provided detailed training to avoid missing out the vital and important information. 
 
CRFs were collected and stored at secured and access controlled place. After that, all 
the CRFs were reviewed second time for any discrepancies. The once the check is 
over, the data entry was performed. Data entry was performed using Microsoft Excel 
2003. 
     
Manual review of CRFs were performed to identify the inconsistencies, which cannot  
be recognized by an electronic check. 
       
9.6 Methodology followed during Data cleaning and Data analysis: 
 
Quality review (QR) was performed to ensure data integrity and quality of the data 
deliverables. Initial QR was performed on received CRFs and lab reports. Wherever, 
we felt the data are doubtful or outliers, we omitted those data from analysis. 
 
9.7 Statistical Analysis: 
 
All statistical tests were considered significant at 5% level of significance. All data 
was analyzed by using Chi square test using SAS version 8.2. 
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Demographic, background and baseline data was presented descriptively. All 
continuous variables like age, height, weight and laboratory data was represented by 
mean +SD (Standard Deviation). All the categorical variables were presented as 
counts and percentages. 
 
Missing Data and Omitted Data: At various stages of the study, we did observe 
missing of the data. We also noticed that some data was not captured and CRFs were 
kept blank for those particular fields.  
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10. RESULTS:  
We have collected data from 1652 subjects during the period of May 2007 to March 2008 
from Urban and Rural area of Ahmedabad, Sabarkantha, Rajkot and Panchmahal districts 
of Gujarat in Western India. 
10.1. Overall prevalence of IFG and IGT:  
    IFG   IGT   
Gender n= 1454 100(%) 1453 100(%) 
  Male 30 2.06 45 3.16 
  Female 10 0.69 44 2.95 
Total 
Crude 
Prevalence 
 40 2.75 89 6.11 
Age 
adjusted 
prevalence 
  2.72%  4.67% 
 
Table 4: Gender wise distribution of IFG and IGT population. 
 
Fig: 8 Graphical presentation of IFG and IGT population 
The collected data suggest that, overall prevalence of IFG in Gujarat is around 2.76% and 
IGT is around 6.12%.But when we applied age related prevalence (133), we found the 
prevalence of IFG is 2.72% and IGT is around 4.67%.  
There are around 10 subjects, who were common in both IFG and IGT groups.  
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10.2 Gender wise presentation of IFG and IGT: 
 
Upon further evaluation, we found that the prevalence of IFG (Impaired Fasting Glucose) 
in male is around 2.06 % and in female population is around 0.69%. 
 
The prevalence of IGT (Impaired Glucose Tolerance) in male is around 3.09% and in 
female is around 2.94%. 
 
10.3 Distribution of IFG and IGT population in Urban and Rural area: 
 
Area IFG IGT 
Rural    (n= 822) 38 (4.62%) 34 (4.32%) 
Urban   (n= 855) 02 (0.23%) 50 (5.84%) 
Total 40 84 
 
Based on the above information, we can conclude that the prevalence of IFG and IGT is 
more in urban and rural area. 
 
10.4 Age wise prevalence of IFG and IGT:  
 
 
 
 
 
 
 
 
 
Table 5: Age wise prevalence of IFG & IGT 
 
 Category        Age              
Group 
                        (in years) 
                    
IGT (N=984) IFG( N=985) 
I <= 30 1 2 
II 31 – 40 3 2 
III 41 – 50 34 9 
IV 51 – 60 19 9 
V >= 60 10 9 
 
 
 
Page 46 of 107 
Agewise Prevance of IFG and IGT
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Fig 9: Agewise prevalence of IFG and IGT 
 
From the above data, we can conclude that the prevalence of IFG and IGT increases, as 
the age progresses. From these data, it can be also proven that, prediabetes prevalence 
significantly start increasing after the age more than 41 years and after that it starts 
reducing. It means the and alertness for prevention of prediabetes is required age of 40 
years to prevent prediabetes development and later on diabetes.  
 
10.5 Characteristics of Population: 
 
In this study, we characterised the population based on their BMI, WHR, Systolic and 
Diastolic blood pressure for both the sub groups (IFG and IGT)as given in below table. 
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Table 6: Characteristics of IFG Population: 
 
Category Statistical 
tool 
BMI 
(kg/m2) 
Waist/Hip 
Ratio 
Systolic Blood 
Pressure 
(mm Hg) 
Diastolic 
Blood 
Pressure 
(mm Hg) 
Normoglycemic  N 1246 1208 1240 1239 
(< 110 mg/dl) MIN-MAX 13.76-57.67 0.54-1.62 70.00-220.00 48.00-170.00 
  MEAN±SD 25.66±5.22 0.91± 0.09 123.27 ± 15.03 81.44 ± 9.61 
 
IFG(>110 - 
<126 mg/dl) 
N 38 35 39 39 
MIN-MAX 19.95-35.44 0.80-1.13 100.00-196.00 60.00-100.00 
MEAN±SD 26.81± 4.21 0.96 ± 0.07 135.54 ± 21.45 82.92 ± 9.97 
 
Newly 
Diagnosed 
Diabetes(>126 
mg/dl) 
N 79 68 77 77 
MIN-MAX 17.15-36.00 0.82-1.60 96.00-200.00 58.00-110.00 
MEAN±SD 26.62 ± 3.61 0.97± 0.11 132.39 ± 19.69 83.94 ± 9.60 
 
In IFG population, the mean value of BMI is 26.81 + 4.21 kg/m2, WHR is 0.96 + 0.07, 
Systolic blood pressure is 135.54 + 21.45 mm Hg and Diastolic blood pressure 82.92 + 
9.97 mm Hg. 
 
This proves that BMI and WHR is highly significant statistically in IFG population. The 
result proves that IFG population is more prone to develop central obesity.  
 
Similarly, mean systolic and diastolic blood pressure is more in IFG population as 
compare to normoglycemic population. This proves that blood pressure is also risk factor 
for development of prediabetes. 
 
The observation in IFG population was correlated with newly diagnosed subjects. It 
means the probability of risk for prediabetes is as high as diabetes population. 
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            Table 7: Summary of normoglycemic, IFG and newly diagnosed diabetes subjects by BMI, WHR, Systolic and  
               Diastolic blood pressure: 
Category BMI 
(kg/m2) 
Waist to Hip Ratio Systolic Blood Pressure 
       (mm Hg) 
Diastolic blood Pressure 
     (mm Hg) 
Male Female 
  Total < 25 > 25 Total < 0.95 > 0.95 Total < 0.85 > 0.85 Total <120 >120 Total <80 >80 
Fasting 
Blood 
Glucose 
1363  
(100) 
652 
(47.84) 
711 
(52.16) 
795  
(100) 
501 
(63.02) 
294 
(36.98) 
516 
(100) 
232 
(44.96) 
284 
(55.04) 
1356 
(100) 
708 
(52.21) 
648 
(47.79) 
1355        
(100) 
801 
(59.11) 
554 
(40.89) 
Normoglyc
emic 
(<110 
mg/dl) 
1246  
(91.42) 
614  
(45.05) 
632  
(46.37) 
730 
(91.82) 
477 
(60.00) 
253  
(31.82) 
478 
(92.64) 
223 
(43.22) 
255  
(49.42) 
1240 
(91.45) 
670  
(49.51) 
570 
(42.04) 
1239    
(91.44) 
742 
(54.76) 
497 
(36.68) 
IFG 
>110 <126 
mg/dl 
38  
(2.79) 
13  
(0.95) 
25  
(1.83) 
26  
(3.27) 
10  
(1.26) 
16 
(2.01) 
9 
(1.74) 
2 
(0.39) 
7  
(1.36) 
39 
(2.88) 
14 
(1.03) 
25           
(1.84) 
39          
(2.88) 
21 
(1.55) 
18 
(1.33) 
Newly 
Diagnosed 
Diabetes  
(>126 
mg/dl) 
79  
(5.80) 
25  
(1.83) 
54  
(3.96) 
39 
(4.91) 
14 
(1.76) 
25 
(3.14) 
29 
(5.62) 
7 
(1.36) 
22 
(4.26) 
77 
(5.68) 
24 
(1.77) 
53 
(3.91) 
77 
(5.68) 
38 
(2.80) 
39 
(2.88) 
P-value 0.0023 
 
 
<0.0001 
 
 
0.0233 
 
 
<.0001 
 
 
0.1502 
 
 
* 42 subjects data were missing and hence not considered for analysis. 
             Note: P-value obtained using chi-square test. 
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 Above table shows that; 
BMI: subjects with BMI greater than equal to 25 have more chances of becoming 
diabetic, 25 (1.83%) versus 13 (0.95%). Also in this category, more no. of newly 
diagnosed diabetes has been identified 54 (3.96%) versus 25 (1.83%).  
 
A p-value of 0.0023, obtained using chi-square test, indicates this association is 
statistically significant. 
 
Waist to hip ratio: Male subjects with waist to hip ratio > 0.95 have more chances of 
becoming diabetic, 16 (2.01%) versus 10 (1.26%). A p-value of <0.0001, obtained using 
chi-square test, indicates this association is statistically significant.  
 
For female subjects with waist to hip ratio > 0.85 have more chances of becoming 
diabetic, 7 (1.36%) versus 2 (0.39%). A p-value of 0.0233, obtained using chi-square test, 
indicates this association is statistically significant.  
 
Blood Pressure: Subjects with systolic blood pressure greater than 120 mm Hg have 
more chances of becoming diabetic, 25 (1.84%) versus 14 (1.03%). A p-value of 
<0.0001, obtained using chi-square test, indicates this association to be statistically 
significant. 
 
While for diastolic blood pressure, there is inverse relationship noted. 
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Table 8: Characteristics of IGT Population: 
 
Category I:  Subjects, 2 hr post glucose value < 140 mg/dl 
Category II: Subjects with 2 hr post glucose value 140-200 mg/dl (Impaired glucose 
Tolerance) 
 
* 78 subjects with blood glucose value more than 200 mg/dl were excluded from the 
analysis. 
In IGT population, the mean value of BMI is 29.36 + 6.49 kg/m2, WHR is 0.94 + 0.12, 
Systolic blood pressure is 130.19 + 17.66 mm Hg and Diastolic blood pressure 83.64 + 
9.43 mm Hg.    
This proves that BMI and WHR is highly significant statistically in IGT population. This 
is suggestive that, IGT population is more prone to develop obesity.  
Similarly, mean systolic and diastolic blood pressure is more in IGT population as 
compare to category I population. This proves that blood pressure is also risk factor for 
development of prediabetes. 
 
And hence, the above findings strongly propose that the BMI, WHR, systolic blood 
pressure and diastolic blood pressure are risk factors in IFG and IGT population.
Category Statistical 
tool 
BMI 
(kg/m2) 
Waist/Hip 
Ratio 
Systolic Blood 
Pressure 
(mm Hg) 
Diastolic 
Blood 
Pressure 
(mm Hg) 
I:2h Post Glucose 
<140 mg/dl * 
N 1229 1189 1220 1219 
MIN-MAX 13.76-85.22 0.54-1.60 44.00-368.00 10.00-170.00 
MEAN±SD 25.57± 5.21 0.91±0.09 123.94 ± 17.18 81.43 ± 9.96 
 
II: Impaired Glucose 
Tolerance(IGT) (2 h 
post glucose 140-
200 mg/dl) 
N 84 74 83 83 
MIN-MAX 16.23-57.67 0.55-1.62 86.00-196.00 60.00-100.00 
MEAN±SD 29.36± 6.49 0.94±0.12 130.19± 17.66 83.64± 9.43 
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Table 9: Summary of IGT subjects by BMI, WHR, Systolic and Diastolic blood pressure: 
 
Category BMI(kg/m2) Waist to Hip Ratio Systolic Blood Pressure 
(mm of Hg) 
Diastolic blood Pressure 
(mm of Hg) Male Female 
 Total < 25 > 25 Total < 0.95 > 0.95 Total < 0.85 > 0.85 Total <120 >120  Total <80 >80 
2 h Post 
Glucose 
1313 
(100) 
624 
(47.52) 
689 
(52.48) 
757 
(100) 
479 
(63.28) 
278 
(36.72) 
506 
(100) 
226 
(44.66) 
280 
(55.34) 
1303 
(100) 
681 
(52.26) 
622 
(47.74) 
1302 
(100) 
765 
(58.86) 
537 
(41.24) 
2h Post 
Glucose (<140 
mg/dl) 
1229 
(93.60) 
605 
(46.08) 
624 
(47.52) 
717 
(94.72)   
467 
(61.69) 
250 
(33.03) 
472 
(93.28) 
213 
(42.09) 
259 
(51.19) 
1220 
(93.63) 
649 
(49.81) 
571 
(43.82) 
1219 
(93.63) 
728 
(55.91) 
491 
(37.71) 
Impaired 
Glucose 
Tolerance(IG
T) (2 h post 
glucose 140-
200 mg/dl) 
84 
(6.40) 
19 
(1.45) 
65 
(4.95) 
40 
(5.28) 
12 
(1.59) 
28 
(3.70) 
34 
(6.72) 
13 
(2.57) 
21 
(4.15) 
83 
(6.37) 
32 
(2.46) 
51 
(3.91) 
83 
(6.37) 
37 
(2.84) 
46 
(3.53) 
P-value < 0.0001 < 0.0001 0.2003 0.0098 0.0067 
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Above table shows that; 
BMI: Subjects with BMI > to 25 have more chances for development of Impaired 
Glucose Tolerance 65 (4.95%) versus 19 (1.45%).  
A p-value of <0.0001, obtained using chi-square test, indicates this association to be 
statistically significant. 
 
Waist to hip ratio: Male subjects with waist to hip ratio greater than equal 0.95 have 
more chances of development  of Impaired Glucose Tolerance 28 (3.70%) versus 12 
(1.59%). A p-value of <0.0001, obtained using chi-square test, indicates this association 
is statistically significant.  
 
For female subjects with waist to hip ratio greater than equal 0.85 have more chances of 
development  of Impaired Glucose Tolerance 21 (4.15%) versus 13 (2.57%). A p-value of 
0.2003, obtained using chi-square test, indicates this association is not statistically 
significant.  
 
Blood Pressure: Subjects with systolic blood pressure greater than 120 have more 
chances of development  of Impaired Glucose Tolerance , 51 (3.91%) versus 32 (2.46%).  
A p-value of 0.0098 obtained using chi-square test, indicates this association to be 
statistically significant. 
 
Subjects with diastolic blood pressure greater than 80 have more chances of development  
of Impaired Glucose Tolerance , 46 (3.53%) versus 37 (2.84%).  
 
A p-value of 0.0067 obtained using chi-square test, indicates this association to be 
statistically significant. 
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10.6 Lipid Analysis in Prediabetes Population: 
 
Table 10: Summary of Lipid Analysis for Normoglycemic, IFG and newly diagnosed 
diabetes population: 
 
Category Statistical 
tool 
Serum 
Cholesterol 
(mg/dl) 
HDL 
Cholesterol 
(mg/dl) 
LDL 
Cholesterol 
(mg/dl) 
Serum 
Triglycerides 
(mg/dl) 
Normoglycemic  
(< 110 mg/dl) 
  
  
N 1330 1329 1329 1330 
MIN- MAX 31.40-360.50 14.00-57.20 66.90-225.30 59.30-870.10 
MEAN±SD 203.02±38.24 44.55±4.68 131.55±25.56 141.66±70.83 
          
IFG(>110 <126 
mg/dl) 
N 40 40 40 40 
MIN- MAX 129.90-293.70 38.10-56.90 67.60-193.90 70.90-489.70 
MEAN±SD 206.83±51.28 45.77±5.95 130.47±35.61 178.44±94.18 
            
Newly Diagnosed 
Diabetes(>126 
mg/dl) 
N 89 89 89 89 
MIN- MAX 104.10-310.40 37.00-57.10 65.80-192.70 73.70-612.90 
MEAN±SD 206.23±45.49 45.05±5.21 126.35±32.23 193.21±96.52 
 
The above mentioned data suggest that, Sr.tryglycerides is highly significant statistically 
in IFG population as compare to normoglycemic.It also matches with the findings from 
various studies in the Indian population. 
 
IFG population has more Sr.tryglycerides, as compare to normoglycemic population. The 
result from the data proves our assumptions that, IFG population is more prone to 
develop dyslipidemia.  
Similarly for other lipid parameters such as Sr.Cholesterol,HDL-C and LDL-C is also 
elevated in IFG population but not highly significant statistically.  
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Table 11: Profile of normoglycemic, IFG and newly diagnosed diabetes population by their lipids: 
 
 
 
 
 
 
Category Serum Cholesterol(mg/dl) HDL Cholesterol (mg/dl) LDL Cholesterol(mg/dl) Serum Triglycerides (mg/dl) 
Male Female 
  Total < 200 > 200 Total < 40 > 40 Total < 50 > 50 Total <130 >130 Total <150 >150 
Fasting Blood 
Glucose 
1442  
(100) 
713 
(49.85) 
729 
(50.55) 
855  
(100) 
718 
(83.98) 
137 
(16.02) 
586 
(100) 
65 
(11.09) 
521 
(88.91) 
1441 
(100) 
724 
(50.24) 
717 
(49.76) 
1442       
(100) 
921 
(63.87) 
521 
(36.13) 
Normoglyce
mic 
(<110 mg/dl) 
1316 
(91.26) 
650  
(45.08) 
666 
(46.19) 
781 
(91.35) 
655 
(76.37) 
128 
(14.97) 
534 
(91.13) 
55 
(9.39) 
479 
(81.74) 
1315 
(91.26) 
652  
(45.25) 
663 
(46.01) 
1316   
(91.26) 
866 
(60.06) 
450 
(31.21) 
IFG 
>110 <126 
mg/dl 
40 
(2.77) 
20 
(1.39) 
20 
(1.39) 
30 
(3.51) 
25 
(2.92) 
5 
(0.58) 
10 
(1.71) 
4 
(0.68) 
6 
(1.02) 
40 
(2.78) 
22 
(1.53) 
18              
(1.25) 
40          
(2.77) 
20 
(1.39) 
20 
(1.39) 
Newly 
Diagnosed 
Diabetes  
(>126 mg/dl) 
86 
(5.96) 
43 
(2.98) 
43 
(2.98) 
44 
(5.15) 
40 
(4.68) 
4 
(0.47) 
42 
(7.17) 
6 
(1.02) 
36 
(6.14) 
86 
(5.97) 
50 
(3.47) 
36 
(2.50) 
86 
(5.96) 
35 
(2.43) 
51 
(3.54) 
P-value 
0.8950 0.4364 0.0098 0.02545 <0.001 
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Above table shows that, subjects with Sr.tryglycerides greater than equal to 150 have 
more chances for development of Impaired Fasting Glucose.  
A p-value of <0.0001, obtained using chi-square test, indicates this association to be 
statistically significant. 
Table 12: Summary of Lipid Analysis for IGT population: 
 
Category I:  Subjects, 2 hr post glucose value < 140 mg/dl. 
Category II: Subjects with 2 hr post glucose value 140-200 mg/dl (Impaired glucose 
Tolerance) 
* 59 subjects with 2 hr blood glucose value more than 200 mg/dl were excluded from the 
analysis. 
The above mentioned data suggest that, there is significant difference in Sr.triglycerides 
value in Category I compared to IGT population. 
 
IGT population also has more Sr.triglycerides, as compare to category I. The above result 
proves our assumption that IGT population is more prone to develop diabetic 
dyslipidemia. This finding could be unique for Gujarati population that, they have higher 
triglycerides. Other laboratory parameters may be found abnormal but our study has 
Category Statistics Serum 
Cholesterol 
(mg/dl) 
Serum HDL 
Cholesterol 
(mg/dl) 
LDL 
Cholesterol 
(mg/dl) 
Serum 
triglycerides 
(mg/dl) 
I :2h Post 
Glucose (<140 
mg/dl)* 
N 1369 1368 1368 1369 
MIN- MAX 31.40-360.50 14.00-57.20 65.80-225.30 59.30-870.10 
MEAN±SD 203.59±39.10 44.64±4.78 131.70±26.16 143.91±74.01 
 
II:Impaired 
Glucose 
Tolerance(IGT) 
(2 h post glucose 
>140-200 mg/dl) 
N 89 89 89 89 
MIN- MAX 129.90-87.40 37.00-56.10 67.60-188.40 72.10-489.70 
MEAN±SD 199.68±39.07 44.34±4.36 124.02±28.07 175.23±77.12 
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highlighted significantly about triglycerides and genetically match with Indian population, where they have been labelled with 
hypertriglyceridemia.We can also hypothesize that, other laboratory parameters may be found abnormal after the age of 60 years. 
 Table 13: Profile of IGT population by their lipids: 
 
Above table shows that, subjects with triglycerides greater than 150 have more chances for development  of Impaired Glucose 
Tolerance  53 (3.85%) versus 36 (2.61%).  
A p-value of <0.0001, obtained using chi-square test, indicates this association is statistically significant. 
Category Serum Cholesterol(mg/dl) HDL Cholesterol (mg/dl) LDL Cholesterol(mg/dl) Serum Triglycerides(mg/dl) 
Male Female 
 Total < 200 > 200 Total < 40 > 40 Total < 50 > 50 Total <130 >130 Total <150 >150 
 
2 h Post 
Glucose 
1377  
(100) 
680 
(49.38) 
697 
(50.62) 
808  
(100) 
681 
(84.28) 
127 
(15.72) 
568 
(100) 
63 
(11.09) 
505 
(88.91) 
1376 
(100) 
689 
(50.07) 
687 
(49.93) 
1377        
(100) 
886 
(64.34) 
491 
(35.66) 
2h Post 
Glucose 
(<140 
mg/dl) 
1288 
(93.54) 
634 
(46.04) 
654 
(47.49) 
762 
(94.31) 
642 
(79.46) 
120 
(14.85) 
525 
(92.43) 
55 
(9.68) 
470 
(82.75) 
1287 
(91.26) 
636  
(46.22) 
651 
(47.31) 
1288   
(93.54) 
850 
(61.73) 
438 
(31.81) 
Impaired 
Glucose 
Tolerance(I
GT) (2 h 
post glucose 
140-200 
mg/dl) 
89 
(6.46) 
46 
(3.34) 
43 
(3.12) 
46 
(5.69) 
39 
(4.83) 
7 
(0.87) 
43 
(7.57) 
8 
(1.41) 
35 
(6.16) 
89 
(6.47) 
53 
(3.85) 
36         
(2.62) 
89         
(6.46) 
36 
(2.61) 
53 
(3.85) 
P-value 0.8905 
 
0.9235 0.1027 0.2713 <0.001 
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For HDL-C, in the group of male subjects with HDL-C less than 40 have more chances 
of development of Impaired Glucose Tolerance 39 (4.83%) versus 7 (0.87%). A p-value 
of 0.9235, obtained using chi-square test, indicates this association is statistically 
significant.  
10.7 Family History and Prediabetes: 
 
In this study, we also tried to correlate the prevalence of IFG and IGT in the population 
with the family history of diabetes. The below mentioned table provides the details on the 
same. 
 
Table 14: Correlation of Family History of Diabetes with IFG. 
 
Category Family history of Diabetes 
IFG Positive Negative Total 
Yes 14(3.47%) 389 403(100%) 
No 24 986 960 
Total 38 1325 1363 
Odds ratio 1.5279 p value 0.2962 
 
From the above analysis, we can conclude that, in our study, out of 403(100%) subjects 
of IFG, 14(3.47%) subjects have the family history of diabetes.  
 
Table 15: Correlation of Family History of Diabetes with IGT. 
 
Category Family history of Diabetes 
IGT Positive Negative Total 
Yes 31(8.13%) 350 381(100%) 
No 53 877 930 
Total 84 1227 1311 
Odds ratio 1.5852 p value 0.0683 
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Similarly, out of 381(100%) subjects with IGT, 31(8.13%) has the family history of 
diabetes. Which means the family history plays very important role in the development of 
prediabetes especially for IGT. 
 
Interpretation of Odds Ratio: 
 
In IFG population, odds ratio of 1.5279 suggest that the persons, who have family history 
of diabetes are having 1.5 times more chance to develop IFG compare to the persons, 
who do not have family history of Diabetes. 
 
In IGT population, odds ratio of 1.5852 suggest that the persons who have family history 
of diabetes are having 1.6 times more chance to develop IGT compare to the persons, 
who do not have family history of Diabetes. 
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11. ETHICAL REQUIREMENT: 
 
Prior to initiation of the study, protocol, informed consent form, case record form and 
other relevant study documents were submitted to the Institutional ethics committee of 
B.J.Medical College and Civil Hospital, Ahmedabad. And after receiving the approval, 
study was initiated. The study was conducted as per Schedule Y and ICH GCP 
guidelines. We have also followed the Declaration of Helsinki guidelines. 
11.1 Patient Information and Consent: 
 
No patient is subjected to any study-related examination or activity before that patient 
and/or legal guardian has given informed consent. Written informed consent was 
obtained from all the subjects. 
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12. DISCUSSION:  
Diabetes is the main cause of kidney failure, limb amputations and new onset blindness 
in adults and is a major cause of heart disease and stroke. Many clinical trials have 
proven that, these complications can be dramatically reduced with tight control of blood 
glucose, blood pressure and cholesterol. National campaigns such as the National 
Diabetes Education Program’s “Be Smart about your Heart. Control the ABCs of 
Diabetes” (HbA1c, Blood Pressure, and Cholesterol) have led to a wider awareness of the 
need to control the risk factors for diabetes complications (134). 
Only less than 12 percent of people diagnosed with diabetes meet the recommended goals 
for blood glucose, blood pressure, and cholesterol despite a great deal of research 
showing that controlling these conditions dramatically delays or prevents diabetes 
complications. Moreover, the percentage of people who achieve these targets has 
changed little in the last decade (134).  
 
Epidemiological analyses of the Diabetes Control and Complications Trial Research 
Group (DCCT) and UKPDS demonstrate a curvilinear relationship between A1C and 
microvascular complications (136-137). 
Such analysis suggest that, on a population level, the greatest number of complications 
will be prevented by transferring patients from very poor control to fair or good control. 
These analyses also suggest that further lowering of A1C from 7 to 6% is associated with 
further reduction in the risk of microvascular complications, though the absolute risk 
reductions become much smaller.  
Many epidemiologic studies and meta-analyses have clearly shown a direct relationship 
between A1C and CVD, the potential of intensive glycemic control to reduce CVD has 
been less clearly defined.  
 
In the DCCT, there was a trend toward lower risk of CVD events with intensive control.  
 
However, 9-year post-DCCT follow-up of the cohort has shown that participants 
previously randomized to the intensive arm had a 42% reduction (P = 0.02) in CVD 
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outcomes and a 57% reduction (P = 0.02) in the risk of nonfatal myocardial infarction 
(MI), stroke, or CVD death compared with those previously in the standard arm (138-
140).  
 
The ADA and the EASD published an expert consensus statement on the approach to the 
management of hyperglycemia in individuals with type 2 diabetes (141). Highlights of 
this approach are: intervention at the time of diagnosis with metformin in combination 
with lifestyle changes (MNT and exercise) and continuing timely augmentation of 
therapy with additional agents (including early initiation of insulin therapy) as a means of 
achieving and maintaining recommended levels of glycemic control (i.e., A1C <7% for 
most patients). Whenever A1C targets are not achieved, treatment intensification is based 
on the addition of another agent from another class. 
People with diabetes should be advised to perform at least 150 min/week of moderate-
intensity aerobic physical activity (50–70% of maximum heart rate).In the absence of 
contraindications, people with type 2 diabetes should be encouraged to perform resistance 
training three times per week.  
Structured exercise interventions of at least 8 weeks duration have been shown to lower 
A1C by an average of 0.66% in people with type 2 diabetes, even with no significant 
change in BMI (142).  
Assessment of psychological and social situation should be included as an ongoing part 
of the medical management of diabetes.  
Psychological and social problems can impair the individual's or family's ability to carry 
out diabetes care and therefore compromise health status. There are opportunities for the 
clinician to assess psychosocial status in a timely and efficient manner, so that referral for 
appropriate services can be accomplished (143-145). 
 
The present study provides the first representative, population based estimates of 
Prediabetes (IFG & IGT) in Urban & Rural Gujarati community.  
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This study was designed to give the reliable state wise estimates of diabetes prevalence, 
as commonly people believes that Gujarati community have high affinity to Diabetes 
because of their food habit and affluent lifestyle. 
 
Various epidemiological studies conducted in India during year 2000 to 2005 have shown 
the varied prevalence of Diabetes in Indian population. Out of these if, we review the 
studies conducted in western part of India (Yagnik et al from Pune in 2004 & Iyer et al 
from Dombivali in 2004, as per WHO guidelines) has shown the prevalence of 4.3%  and 
4.01% respectively (146). 
 
Our study has also shown the crude prevalence of IFG in Gujarati population is around 
2.76% and IGT is around 6.12%. But the age adjusted prevalence of IFG is around 2.72% 
and IGT is around 4.67%, which is comparable to the prevalence observed in other 
studies conducted in the past across the globe.  
 
A recent survey in a rural area in 2003 showed indications of transition in the lifestyle of 
rural population and striking increase in the rate of prevalence of diabetes was noted 
(6.3%)(148-149).Our study shows that the prevalence of IFG in Rural area is around 4.62 
% and IGT is around 4.32%. 
  
Lifestyle changes due to urbanisation and aging of the population are two important 
determinant of rising prevalence of prediabetes (IFG & IGT) in developing countries 
such as India. 
 
In an analysis of six prospective studies, the risk of developing diabetes was found to be 
approximately 3.6 to 8.7 percent per year in patients with IGT (147). 
 
IFG and IGT frequently are associated with metabolic syndrome. The Adult Treatment 
Panel III of the National Cholesterol Education Program has identified metabolic 
syndrome as a constellation of lipid and non lipid risk factors for coronary artery disease 
(148). 
 
 
 
Page 63 of 107 
The syndrome is characterized by insulin resistance, atherogenic dyslipidemia (high 
triglyceride level, low high-density lipoprotein cholesterol level, and small, dense low-
density lipoprotein cholesterol particles), hypertension, abdominal obesity and 
prothrombotic and proinflammatory states. 
 
As obesity or an increase in intra abdominal adipose tissue is associated with insulin 
resistance in the absence of diabetes, it is believed by some that, insulin resistance in type 
2 diabetes is entirely due to the coexistence of increased adiposity (149).  
 
We also noticed higher BMI, WHR, higher systolic blood pressure and diastolic pressure 
in IFG and IGT population in our study. 
 
Compared with normoglycemic persons, patients with IGT are at substantially greater 
risk of developing cardiovascular disease (150). 
 
We have also counseled all the subjects to have control diet mainly to curtail the 
carbohydrate to reduce the serum try glycerides.Changes in serum triglyceride and HDL 
cholesterol were more favorable with the low-carbohydrate diets. In one study, those 
subjects with type 2 diabetes demonstrated a greater decrease in A1C with a low-
carbohydrate diet than with a low-fat diet (151). 
 
Plasma levels of LDL-C generally do not differ significantly from those in patients 
without diabetes, but qualitative changes in LDL-C particles make them highly 
atherogenic (152-157). In our study,we also found that LDL-C is not much 
altered.However,we have noticedmore changes in Sr.Tryglyceride. In IFG the mean 
Sr.Tryglyceride is 178.44 + 94.18 mg/dl and in IGT it is 175 +   77.12 mg/dl.This is 
highly correlated with other facts in Indian population. 
 
The primary goal with respect to dietary fat in individuals with diabetes is to limit 
saturated fatty acids, trans fatty acids, and cholesterol intake, so as to reduce risk for 
CVD.  
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We have also concluded that men have higher prevalence of IFG and IGT than female. 
This also matches with the observations from other international studies. The probable 
hypothesis for this development could be disturbances in glucose metabolism, accelerate 
the process of endothelial dysfunction. 
Studies have also confirmed that prevalence of IFG and IGT is increasing as the age 
progresses. Most common in adults over age 40, this form of diabetes is strongly linked 
to obesity, inactivity, family history of diabetes, and racial or ethnic background. Our 
study has also proven the same and hence we are strongly recommending the control 
and/or precautions to be taken after age 40. 
 
Obesity has an effect of on insulin resistance and hence weight loss is an important 
therapeutic objective for overweight or obese individuals with prediabetes or diabetes 
(158).  
Obesity and a high fat diet may contribute to the development of both insulin resistance 
and insulin secretary dysfunction in susceptible individuals. Strategies that improve 
insulin resistance and enhance early insulin secretion may prevent the progression from 
IGT to diabetes. Already, there is substantial evidence the weight loss and exercise may 
reduce the risk of developing diabetes by up to 58% (159).  
 
In our study, we have also noticed the higher mean BMI 26.81 + 4.21 kg/m2 and waist to 
hip ration 0.96 + 0.07 in IFG population. Similarly for IGT population, where mean BMI 
is 29.36 + 6.49 kg/m2, WHR is 0.94 + 0.12. This is more than the normoglycemic 
population. Hence, it proves that IFG and IGT population is more prone to develop 
obesity. 
Patients with impaired glucose tolerance or impaired fasting glucose have a significant 
risk of diabetes and thus are important target for primary prevention (160). 
 
At present, India is in the verge of a rapid epidemiological transition with increased 
urbanization. Present urbanization rate is 35% compared to 15% in the 1950’s and this 
could have major implications on the present and future disease patterns in India with 
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context to diabetes and coronary artery disease. Socio-economic development over the 
last 40-50 years has resulted in a dramatic change in lifestyle towards more 
westernization, leading to physical inactivity due to technological advancement, 
affluence leading to consumption of fat rich diet, sugar and high level of mental stress. 
All these could adversely influence insulin sensitivity and lead to obesity (161).  
 
Since 1970, several studies have been done comparing urban and rural populations in 
India, which have shown higher prevalence of diabetes among urban residents compared 
to their rural counterparts both in southern and northern parts of India (162).In this study, 
we found the prevalence of IFG in urban area is 4.32% and in rural area is 2.18%. But the 
prevalence of IGT in urban area is 5.84% and in rural is also 4.26%. We found 
prevalence of IFG and IGT is more in urban area. 
 
In diabetic subjects, some surrogate measures of vascular pathology, such as endothelial 
dysfunction, are negatively affected by postprandial hyperglycemia (163). Studies have 
also confirmed that circulating endothelium factors (mainly PAI-I) are more in IGT and 
IFG population. This leads to the damage in the endothelial cells (164-165).  
 
Currently, since last decade the percentage of people with diagnosed diabetes taking 
blood pressure medication has grown, around 36 percent of participants in the most 
recent NHANES met ADA’s current blood pressure goal of less than 130/80 mmHg and 
40 percent had high blood pressure. Around ~23% of Americans aged 20 to 74 years 
have high blood pressure (i.e, systolic blood pressure >140 mm Hg or diastolic blood 
pressure >90 mm Hg); in addition, 25% to 45% of these hypertensive patients are insulin 
resistant and dysmetabolic (166-168). 
 
In our study, we also found the subjects with IFG and IGT had a high blood pressure. In 
IFG population mean systolic blood pressure was 135.54 + 21.45 mm Hg and Diastolic 
blood pressure 82.92 + 9.97 mm Hg, which was higher than normoglycemic population. 
Similarly, for IGT population systolic blood pressure was 130.19 + 17.66 mm Hg and 
Diastolic blood pressure 83.64 + 9.43 mm Hg.  
 
 
 
Page 66 of 107 
We have counseled the subjects for control of blood pressure by non pharmacological 
measures first and then opt for pharmacological measures. 
 
The link between hypertension and atherosclerosis, myocardial infarction and stroke has 
been well established through longitudinal observational research and clinical trials of 
antihypertensive drugs (169).  
 
In nutshell, prediabetes population has high probability for getting converted into 
Diabetes in the long run (may be 3-5 years) (170). In any given year, 5% to 10% of 
glucose-intolerant patients progress to type 2 diabetics (171-173).  
 
And prediabetes also develop diabetes dyslipidemia and lead to morbidity and mortality. 
Therefore, public attention to the high prevalence of IFG and Diabetes is requested. 
 
In addition, first degree relatives of patients with type 2 diabetes have been found to have 
impaired insulin action upon skeletal muscle glycogen synthesis due to both decreased 
stimulation of tyrosine kinase activity of the insulin receptor and reduced glycogen 
synthase activity (174-175).  
 
In our study, we have also correlated that the person who have the history of diabetes has 
1.52 times more possibility of the development of IFG. Similarly, the person who has the 
history of diabetes has 1.58 times more possibility of developing IGT.  
 
We also confirmed that, WHR is statistically significant in both the groups compare to 
the normoglycemic, it is said to be have correlation with Diabetes and Obesity. 
 
HDL has the inverse relation, states that HDL is more in IFG and IGT population as 
compare to the normoglycemic. In the contrary, other lipid parameters such as LDL, 
serum cholesterol and serum triglycerides are elevated in IFG and IGT population and 
have the direct relationship with dyslipidemia and prediabetes. And may lead to diabetes 
dyslipidmia in the long run. 
 
 
 
Page 67 of 107 
 
The management plan should be formulated as a collaborative therapeutic alliance among 
the patient and family, the physician and other members of the health care team. A 
variety of strategies and techniques should be used to provide adequate education and 
development of problem-solving skills in the various aspects of prediabetes management 
early stage.  
There may be possible limitation of the study due to the sample size. 
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13. SUMMARY AND CONCLUSION: 
 
This was the first representative study conducted to evaluate the prevalence of 
Prediabetes in Gujarat. Because of that, it has led highest significance, as till today we are 
relying on the various publications from other part of India and abroad. 
 
From this study we conclude that, overall prevalence of IFG in Gujarat is around 2.72% 
and IGT is around 4.67%. And significantly observed that, the prediabetes prevalence is 
increasing day by day in urban and rural area because of the change in the lifestyle, food 
habit, working culture, affluence.  
 
If we extrapolate with the total population of the state, Gujarat will have be around 1.31 
million people of IFG and 2.30 million people with IGT are present currently. And if, we 
assume the same quantum of rise, than in next 10 years these numbers may become more 
than double i.e. around 4 million of IFG and 5 million of IGT alone. Along with that, if 
we assume the conversion rate from IFG and IGT to diabetes, than every 2-3 years 
around 80,000-140,000 new diabetes are added in to the current population. This is an 
impediment in the economy of the state and nation, as young population is converted into 
diabetes.  
 
Lipid abnormality is also reported in this population along with glucose abnormality.  
This clearly indicates that, in this population along with glucose, we must focus on lipid 
abnormality corrections. Clinicians generally focus only on glucose, but we must focus 
on lipid too, to avoid the development of diabetes dyslipidemia. May be the stage can be 
classified as a pre dyslipidic/metabolic syndrome. 
 
We also need to motivate the population, who are approaching at 40 years because in this 
age we found maximum prevalence of IGT. Even clinically also after this age, the micro 
vascular changes starts and may be precipitate with morbidity. As the morbidity increases 
to this age group it has a significant impact on pharmacoeconomical burden on an 
individual and at nation level. 
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We also evidently correlated, that the person who has family history of diabetes, in that 
group around 3.47% of IFG and 8.13% of IGT are found. Hence as an important point, 
we can first counsel the population, who has history of diabetes. Because this population, 
after age of 35 should start taking precautions to delay their diabetes development. 
 
Also, we counseled the subjects for the diet restrictions mainly for transfat and 
carbohydrate consumption. Along with that the main emphasis was given on the physical 
exercise average around 150 minutes in a week. 
 
As blood pressure is also one of the factors correlated in this population, people must 
focus on distressing exercise to avoid the development of blood pressure. 
 
Gujarat has started rapid urbanization and industrialization after year 2005-06. Our study 
was conducted in 2007 and 2008, when the economic growth of the state was on the pick 
and affluence was also increasing. And hence to maintain the same economics of the state 
and nation, we must focus on the prevention of this deadly disease. 
 
This study has given the new direction in the society and medical fraternity to make 
aware about the status of prediabetes and especially to Endocrinologists, Physicians, 
Healthcare workers, Medical practioners and Common men. We as a group also tried to 
educate to the people through media campaign. Some of the media coverage in national 
English and Gujarati dailies during on 14 November 2011 on the occasion of World 
Diabetes Day is attached herewith. (Appendix-VI). 
 
Striking common attributable risk factors for the same in urban and rural areas are higher 
BMI, Waist to hip ratio, higher systolic and diastolic blood pressure, lipid abnormalities 
mainly higher triglycerides.  
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Our study also established the fact that risk factors, such as ageing and hypertension in 
western Indian population has strong relationship and concurs with the studies in the 
western populations. 
 
Summarising, present study shows that IFG and IGT are associated for developing 
diabetes and they are associated with cardiovascular risk factors in the Western Indian 
population.  
Thus, the findings of present study have important public health implications. Both IFG 
and IGT is not a clinical entity but rather a risk factor for future diabetes and 
cardiovascular disease.  
 
The prediction by WHO, that India is likely to be the country having the largest number 
of diabetic subjects by the year 2025 seems to be true.   
 
And ultimately the message of “Prevention is better than Cure” should be followed to 
avoid the situation. 
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15. APPENDICES:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix I : Informed Consent Form 
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Patient Information 
 
Diabetes is now one of the most common non-communicable diseases globally. This is 
virtually true with reference to Indian subcontinent, which has been declared by the 
World Health Organisation as the “Diabetes Capital of the World”. Prevalence of type 2 
diabetes is rising globally and impact is most marked in developing countries like India. 
Asian Indians have a racial predisposition to develop diabetes. By year 2025 there will be 
more than 75 million (7.5 cr) Indians will be suffering from Diabetes. As per year 2003 
information in Gujarat alone 45 lakh people were suffering from Impaired Glucose 
Tolerance (IGT). Also there will be increase in the population, which will have problem 
of Insulin secretion and Insulin action. 
 
The objectives of the study to determine the prevalence of prediabetes in the rural and 
urban population of Gujarat and also to identify the major risk factors for the increase in 
this incidence.  
 
You will be asked to give blood for the following laboratory investigations. 
 
 Fasting blood glucose 
 2 h Blood Glucose (2 hours after taking 75 gm glucose) 
  Below mentioned tests will be done to assess your lipid profile 
o Total cholesterol 
o Serum Tryglycerides 
o Serum HDL cholesterol  
o Serum LDL cholesterol 
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Patient Consent Form 
 
I ………………………………… exercising my free power of choice, hereby give my 
consent to be included as a subject in the epidemiological study for diabetes. I have been 
informed to my satisfaction, by the attending physician/care taker the purpose of the 
study and the importance of blood withdrawal and follow up including the laboratory 
investigation to monitor and safeguard my body function. 
  
I am also aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
  
Signature of the patient/volunteer________________________ Date:_______________ 
 
Thumb impression of patient, if applicable 
  
  
Date:     Signature of the attending physician/care taker 
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
Page 90 of 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Case Record Form 
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Case Record Form 
 
 
Name of the  Individual : _____________________________________________ 
 
Sex:  Male:     Female:  
 
Date of Birth: ________________ Age: _________ years 
 
Race: Indian_______________ Others:_____________ 
 
Address:_____________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
                  
Area:  Urban                            Rural  
 
Telephone:  STD Code_____  (R) ________________  (O) __________________ 
 
Mobile: ___________________________ 
 
Email Address:_____________________________ 
 
Marital Status:______________________________ 
 
Family Details:  
 
 No.of Family members: ____________________ 
 
 Spouse:__________________________ 
 
 Details of Children(s): _________________________ Age: __________ 
 
 Family History of Diabetes:  Yes___ No___ 
 
 
Details of 
Diabetes:_____________________________________________________________
_____________________________________________________________________ 
_____________________________________________________________________ 
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Previous History of Cardiac Disease: 
 
 
 
Education Level: 
 
High school          Graduate         Post Graduate           Others  
 
Occupation: 
 
Business  Office Job Field Job Farming  Others  
 
Physical activity per Day:  
 
< 30 min/24 hr Sedentary 
30 min-59 min/24 hr  Mild 
> 60 min – 90-min/24 hr Moderate 
> 90 min/24 hr Heavy 
 
Type of Activity: 
 
Cycling   Walking   Plowing  Digging  Gardening   
 
Crop carrying   Manual irrigation  
 
Smoking: Smoker            Nonsmoker  
 
Economic Classification (as per Modified B.G.Prasad): 
 
Per capital Monthly income 
limit (in Rupees) 
Approximately equivalent 
economic status 
2310 and above Upper class -I 
1155-2309 Upper middle-II 
690-1154 Upper Lower-III 
346-689 Lower Middle IV 
< 345 Lower Lower V 
 
Monthly Income: in Rs. ___________________  
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Details about Meals: 
 
a) Vegeterian                     Nonvegetarian             
 
b) Morning Meal: 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
 
c) Evening Meal: 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
 
d) Snacks: 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
 
 
 
Oil consumption:_________________ ml in a day 
 
Milk product consumption:_______________ ml in a day 
 
 
 Carbohydrate:___________________  
 
 Proteins:_______________________ 
 
 Fat:_________________  
 
 Approx.Cal:___________/day
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Demographic Details: 
              
a) Height: _________________ in cm  ______ meter 
 
b) Weight:_________________ in kg 
 
c) Waist: __________________ in cm 
 
d) Hip:_____________________ in cm 
 
e) Waist/Hip ratio:______________ 
 
f) BMI: Weight in kg/Height (m2) ____________ 
 
              
Laboratory Investigations 
 
a) Fasting Blood Glucose_________________mg/dl 
b) 2 h Blood Glucose____________________ mg/dl 
c) Serum Cholesterol_____________________mM /L 
d) Serum Triglycerides___________________ mM/L 
e) Serum HDL Cholesterol_________________mM/L 
f) Systolic Blood Pressure______ mm Hg    
g) Diastolic Blood Pressure________ mm Hg 
 
Comments: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
Name of Investigator:_________________________ 
 
Signature: ____________________ Date:____________________ 
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Appendix III: Ethics Committee Approval Letter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Ethics Committee 
BJMedical College & Civil Hospital, Ahmedabad 
Mel Ilbe r-Secretllr,'j Clmirmmz 
Dr M M'Prabhakar· Dr R [( Dikshit 
Medical Superintendent Professor/Head, Dept of Pharmacology 
Civil Hospital B JMedical College:: 
Ahmedabad 380 016 Ahmedabad 3S0 016 
Ph: 22683721 Ext 1001 Ph: 22683721 Ext 1275 
(Please address all communications to iv/ember-SecrelClI)') 
Ref No. ECI AjO'gj07 
CERTIFICATE OF APPROVAL 
The. Ethics Committee met on 16.5.07 at 3.00 PM at the Office of the Medical 
Superintendent, . Civil Hospitat Ahmedabad. Dr. M. M. Prabhakar, Medical 
Superintendent & Chairman, The Ethics Committee, presided over the 11leeting. 
FClllowing members attended: 
1, Dr R K Dikshit, MD, ProfessorjHeacC Depnrtrrwnt of Pharmacology, B J Medical 
College, Ahmedabad - Member-Secretary. 
2, Dr. G, K. Vankar, MD,Profes';(n,/ Head, Departrnent of~ Psychiatry, B J lVledic<l1 
College & Civil Hospital, Ahmedabad .. Member . 
3. Dr B D Mankad, MD, Professor/Head, Depmtment of Medicine, B J IVk:dical CoJlegl' 
andCiviI Hospital, Alunedabad -lVIember 
4. Dr B J'\ Leuva, MDt Profess';)r, Depcd bllem of Ubstetrics & Gynecolo~y, B .l M.edicaJ 
College & Civil Hospital, Ahmedabad -- Member (in lieu of Dr Malini Desai) 
5. Dr (Mrs) Aruna Dewan, lVlD, Consult,;nt, NIOH, AhlTIedab8d 
6. I'v11' Amar Vyas, MSW, Sl)('ial Woi-kcl', Depi:lrtment of Cornrnunity Mel.1idnc, B I 
Medical College, Ahmedabad - l'v1l'mbl'r 
7, Iv1r P K Yadav, Ll S! Ativocatc, Guj::ll·C\t"/-ligh COUrt - lvkmber 
The Cornmittee reviewed the following project: 
Title: To ass\~ss the prevalence' and nt.tributable risk factors of Lliabl;[," rne!lit, 
western Indian population 
Site where the project will be conduded: Department of lVll'dicim', B ! \lcdical <. ,)Ilcge 
& Civil Hospitat Alunedabad 
Principal Investigator: Dr. Bhagirath B Solanki, Associate Profess\·. uf Medictne, I3 J 
Medical College & Civil HospitaL Ahmedabad 
Sponsors: None 
:""l\l Documents reviewed:Ittf 1. Study synopsis (Protocol) 
2. Product Summary 
3. Informed Consent Form 

-1. Case Record Form 

5. Relevant References (Full Text) 
Subsequent to the fulfillment of the procedura] requirements and other conditions' 
imposed :by the Commitfee the project is hereby granted an approvC\1. The approval is 
for the entire duration aLthe study. Permission to start the work on the same is also 
given, The Principal lnvestig<:ito;' and the Sponsors are required to read ilnd comply 
with the following: 
!':. 1. The Committee has approved the ethical aspects of the proposed \,vmk. However, all other concerns 
,'l,:: 
related to the work (e.g. scientific, procedural, legal, financial and regulatory et::) remain the soil, 
responsibility of the Principal Investigator and/ or the Spo'nsor(s). 
2. The Committee must be informed from time to DIlle ai:lout the progress of thE' worK and a full report 
including the audited statement of accounts should be subrnitted within one month of, the end of this 
work. • . 
3. Any serioLis/unexpected side effects mList b~' cO!11ll1unicatl'd to till' COll1l11jttt~(, Clnd any furth(;,f 
instructions thereupon should be duly foli(lWt'd. 
";::;:·:'~~tlj,;.;I.. .' 
/:;... ~.?-.--~~:;;., ,'~\
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Dr. R. ~l?ftL~!,~;v"i""\' Ahnl~dab<1d 
,";hr Eri;;c:; C();tun;~j,:': D'lt~d, Mil\', 16, 2007 \~~~~;.~::'F)
8. J MNiical Co:Tege ~~ rX";i "!.,srdr,,1 
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. ,·Copy to: 
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--- On Thu, 26/5/11, Siddharth Shah <drsns@jn.com> wrote: 
From: Siddharth Shah <drsns@in.com> 
Subject: japi 
To: shahhchirag@yahoo.com 
Date: Thursday, 26 May, 2011, 3:56 PM 
Jr.No: 152/2011 
Dr. Chirag H. Shah 
E/3, Sthapatya Apartement, 
Nr. Sterling Hospital, 
Opp. Gurukul Road, Memnagar, 
Ahmedabad 380 052. 
Gujarat 
Re.: Original Article entitled "To Assess the Prevalence of 
Impaired Glucose 
Tolerance and Impaired Fasting Glucose in Western India 
Population" 
Dear Dr. Shah, 
Your above article has been received for consideration for 
publication in JAPL The article is being sent to the board of 
referees for scrutiny. We shall let you know about its suitability 
as soon as we receive the comments from the board referees. 
With warm personal regards, 
Yours sincerely, 
Dr. Siddharth N. Shah 
Hon.Editor, JAPI 
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